Relation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data) ; Связь цитокинового профиля и антител к посттрансляционным модификациям белков у пациентов с ревматоидным артритом (предварительные данные)

Συγγραφείς: D. А. Dibrov, А. S. Avdeeva, М. Е. Diatroptov, V. V. Rybakova, Е. L. Nasonov, Д. А. Дибров, А. С. Авдеева, М. Е. Диатроптов, В. В. Рыбакова, Е. Л. Насонов

Συνεισφορές: Работа выполнена за счет средств бюджетного финансирования государственного задания по теме «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний» (номер государственного задания № 1021051402790-6).

Πηγή: Rheumatology Science and Practice; Vol 62, No 2 (2024); 186-191 ; Научно-практическая ревматология; Vol 62, No 2 (2024); 186-191 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: ревматоидный артрит, antibodies to cyclic citrullinated peptide, anti-CCP, antibodies to carbamylated proteins, antiCarp, rheumatoid arthritis, антитела к циклическому цитруллинированному пептиду, АЦЦП, антитела к карбамилированным белкам, анти-Карб

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3548/2365; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; Насонов ЕЛ, Авдеева АС, Дибров ДА. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023;61(3):276-291.doi:10.47360/1995-4484-2023-276-291; Gravallese EM, Firestein GS. Rheumatoid arthritis – Common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529- 542. doi:10.1056/NEJMra2103726; McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115-1123. doi:10.1016/j.autrev.2018.06.001; McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis – Shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63-68. doi:10.1038/nrrheum.2015.171; Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi:10.1136/annrheumdis-2017-211555; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi:10.14412/1995-4484-2017-409-419; Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi:10.47360/1995-4484-2023-397-420; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48. doi:10.1002/art.1780380107; Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22(20):10922. doi:10.3390/ijms222010922; Новиков АА, Александрова ЕН, Диатроптова МА, Насонов ЕЛ. Роль цитокинов в патогенезе ревматоидного артрита. Научно-практическая ревматология. 2010;48(2):71-82. doi:10.14412/1995-4484-2010-1420; Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, MartínezBonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: Associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015;182(2):119-131. doi:10.1111/cei.12677; Reyes-Pérez IV, Sánchez-Hernández PE, Muñoz-Valle JF, Martínez-Bonilla GE, García-Iglesias T, González-Díaz V, et al. Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: Association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity. Clin Rheumatol. 2019;38(11):3061-3071. doi:10.1007/s10067-019-04681-4; Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, et al. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm. 2010;2010:158514. doi:10.1155/2010/158514; Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol. 2004;31(12):2336-2246.; Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: Anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66(6):712-719. doi:10.1136/ard.2006.054924; Новиков АА, Александрова ЕН, Лукина ГВ. Особенности цитокинового профиля при ревматоидном артрите. Альманах клинической медицины. 2019;47(5):393-399. doi:10.18786/2072-0505-2019-47-058; Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(2):383-391. doi:10.1002/art.27186; Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi:10.1371/journal.pone.0035296; Chen Z, Andreev D, Oeser K, Krljanac B, Hueber A, Kleyer A, et al. Th2 and eosinophil responses suppress inflammatory arthritis. Nat Commun. 2016;7:11596. doi:10.1038/ncomms11596; Pan Q, Walls AF, Pan Q. Editorial: Th2-associated immunity in the pathogenesis of systemic lupus erythematosus and rheumatoid arthritis. Front Immunol. 2022;13:975553. doi:10.3389/fimmu.2022.975553; Насонов ЕЛ, Авдеева АС, Коротаева ТВ, Дубинина ТВ, Усачева ЮВ. Роль интерлейкина 17 в патогенезе ревматоидного артрита. Есть ли перспективы применения ингибиторов ИЛ-17? Научно-практическая ревматология. 2023;61(2):165- 180. doi:10.47360/1995-4484-2023-165-180; van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: Possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426. doi:10.1186/s13075-014-0426-z; Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis: A systematic literature review. Rheumatol Ther. 2022;9(2):331-378. doi:10.1007/s40744-021-00407-8; Robert M, Miossec P. IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels. Front Med (Lausanne). 2019;5:364. doi:10.3389/fmed.2018.00364; Gremese E, Tolusso B, Bruno D, Perniola S, Ferraccioli G, Alivernini S. The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 – Unmet needs and therapeutic perspectives. Front Med (Lausanne). 2023;10:956127. doi:10.3389/fmed.2023.956127; Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4(2):e000656. doi:10.1136/rmdopen-2018-000656; McDonald S, Reed R, Baricevic-Jones I, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Ling S, Plant D, et al. Can serum interleukin-17 and interleukin-10 levels predict response to biologic treatments in patients with rheumatoid arthritis? Rheumatology (Oxford). 2019;58(10):1872-1873. doi:10.1093/rheumatology/kez147

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3548
https://doi.org/10.47360/1995-4484-2024-186-191

Comorbidity of rheumatoid arthritis and periodontal diseases ; Коморбидность ревматоидного артрита и заболеваний пародонта

Συγγραφείς: D. I. Trukhan, A. F. Sulimov, L. Yu. Trukhan, Д. И. Трухан, А. Ф. Сулимов, Л. Ю. Трухан

Πηγή: Meditsinskiy sovet = Medical Council; № 5 (2024); 288-297 ; Медицинский Совет; № 5 (2024); 288-297 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: нехирургическое лечение пародонтита, comorbidity, periodontopathic bacteria, Porphyromonas gingivalis, antibodies to cyclic citrullinated peptide, intestinal microbiome, hyperepithelial permeability syndrome, mouth-gut axis, non-surgical treatment of periodontitis, пародонтопатические бактерии, антитела к циклическому цитруллинированному пептиду, микробиоценоз кишечника, синдром повышенной эпителиальной проницаемости, ось «рот – кишечник»

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8250/7272; Трухан ДИ, Филимонов СН, Викторова ИА. Клиника, диагностика и принципы лечения основных ревматических болезней. СПб.: СпецЛит; 2023. 239 с. Режим доступа: https://www.elibrary.ru/mvzgbg.; Насонов ЕЛ, Лила АМ, Каратеев ДЕ, Мазуров ВИ, Амирджанова ВН, Белов БС и др. Ревматоидный артрит: клинические рекомендации. М.; 2021. 112 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/250_2.; Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41:863–877. https://doi.org/10.1007/s00296-020-04731-0.; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8.; Янушевич ОО, Кузьмина ЭМ, Максимовский ЮМ, Малый АЮ, Дмитриева ЛА, Ревазова ЗЭ и др. Клинические рекомендации (протоколы лечения) при диагнозе пародонтита. 2014. Режим доступа: https://e-stomatology.ru/director/protokols.; Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host Modulation and Treatment of Periodontal Disease. J Dent Res. 2021;100(8):798–809. https://doi.org/10.1177/0022034521995157.; Трухан ДИ, Трухан ЛЮ. Взаимоотношения болезней пародонта и сердечно-сосудистых заболеваний. Международный журнал сердца и сосудистых заболеваний. 2016;4(11):15–24. https://doi.org/10.24412/2311-1623-2016-11-15-24.; Van Dyke TE, Starr JR. Unraveling the link between periodontitis and cardiovascular disease. J Am Heart Assoc. 2013;2(6):e000657. https://doi.org/10.1161/JAHA.113.000657.; O’Dwyer MC, Furgal A, Furst W, Ramakrishnan M, Capizzano N, Sen A, Klinkman M. The Prevalence of Periodontitis Among US Adults with Multimorbidity Using NHANES Data 2011–2014. J Am Board Fam Med. 2023;36(2):313–324. https://doi.org/10.3122/jabfm.2022.220207R1.; Del Pinto R, Landi L, Grassi G, Marco Sforza N, Cairo F, Citterio F et al. Hypertension and periodontitis: A joint report by the Italian society of hypertension (SIIA) and the Italian society of periodontology and implantology (SIdP). Oral Dis. 2023;(2):803–814. https://doi.org/10.1111/odi.14009.; Pietropaoli D, Cairo F, Citterio F, D’Aiuto F, Ferri C, Grassi G et al. Practical Guidelines for Patients with Hypertension and Periodontitis. High Blood Press Cardiovasc Prev. 2023;(1):7–16. https://doi.org/10.1007/s40292-022-00553-2.; Leishman SJ, Do HL, Ford PJ. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol. 2010;2(1):5781. https://doi.org/10.3402/jom.v2i0.5781.; Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Periodontol. 2013;84(4):51–69. https://doi.org/10.1902/jop.2013.134006.; Badran Z, Struillou X, Verner C, Clee T, Rakic M, Martinez MC et al. Periodontitis as a risk factor for systemic disease: Are microparticles the missing link? Med Hypotheses. 2015;84(6):555–556. https://doi.org/10.1016/j.mehy.2015.02.013.; Williams RC, Offenbacher S. Periodontal medicine: the emergence of a new branch of periodontology. Periodontol 2000. 2000;23:9–12. https://doi.org/10.1034/j.1600-0757.2000.2230101.x.; Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev. 2000;13(4):547–558. https://doi.org/10.1128/CMR.13.4.547.; Yamazaki K. Oral-gutaxisas a novel biological mechanism linking periodontal disease and systemic diseases: A review. Jpn Dent Sci Rev. 2023;59:273–280. https://doi.org/10.1016/j.jdsr.2023.08.003.; Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of rheumatic arthritis. Nat Rev Rheumatol. 2017;13(10):606–620. https://doi.org/10.1038/nrrheum.2017.132.; Bartold PM, Lopez-Oliva I. Periodontitis and rheumatoid arthritis: An update 2012-2017. Periodontol 2000. 2020;83:189–212. https://doi.org/10.1111/prd.12300.; Kobayashi T, Bartold PM. Periodontitis and periodontopathic bacteria as risk factors for rheumatoid arthritis: A review of the last 10 years. Jpn Dent Sci Rev. 2023;59:263–272. https://doi.org/10.1016/j.jdsr.2023.08.002.; Leech MT, Bartold PM. The association between rheumatoid arthritis and periodontitis. Best Pract Res Clin Rheumatol. 2015;29(2):189–201. https://doi.org/10.1016/j.berh.2015.03.001.; de Molon RS, Rossa C Jr, Thurlings RM, Cirelli JA, Koenders MI. Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions. Int J Mol Sci. 2019;20(18):4541. https://doi.org/10.3390/ijms20184541.; Li R, Tian C, Postlethwaite A, Jiao Y, Garcia-Godoy F, Pattanaik D et al. Rheumatoid arthritis and periodontal disease: What are the similarities and differences? Int J Rheum Dis. 2017;20(12):1887–1901. https://doi.org/10.1111/1756-185X.13240.; Kobayashi T, Yoshie H. Host Responses in the Link Between Periodontitis and Rheumatoid Arthritis. Curr Oral Health Rep. 2015;2(1):1–8. https://doi.org/10.1007/s40496-014-0039-2.; Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett. 2012;333:1–9. https://doi.org/10.1111/j.1574-6968.2012.02579.x.; Du Q, Ma X. Research progress of correlation between periodontal pathogens and systemic diseases. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(5): 759–764. https://doi.org/10.12122/j.issn.1673-4254.2020.05.24.; Xu W, Zhou W, Wang H, Liang S. Roles of Porphyromonas gingivalis and its virulence factors in periodontitis. Adv Protein Chem Struct Biol. 2020;120:45–84. https://doi.org/10.1016/bs.apcsb.2019.12.001.; Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10:717–725. https://doi.org/10.1038/nrmicro2873.; Zheng S, Yu S, Fan X, Zhang Y, Sun Y, Lin L et al. Porphyromonas gingivalis survival skills: Immune evasion. J Periodontal Res. 2021;56(6):1007–1018. https://doi.org/10.1111/jre.12915.; Gasmi Benahmed A, Kumar Mujawdiya P, Noor S, Gasmi A. Porphyromonas Gingivalis in the Development of Periodontitis: Impact on Dysbiosis and Inflammation. Arch Razi Inst. 2022;77(5):1539–1551. https://doi.org/10.22092/ARI.2021.356596.1875.; Li Y, Lu Z, Zhang X, Yu H, Kirkwood KL, Lopes-Virella MF, Huang Y. Metabolic syndrome exacerbates inflammation and bone loss in periodontitis. J Dent Res. 2015;94:362–370. https://doi.org/10.1177/0022034514561658.; Kuraji R, Fujita M, Ito H, Hashimoto S, Numabe Y. Effects of experimental periodontitis on the metabolic system in rats with diet-induced obesity (DIO): an analysis of serum biochemical parameters. Odontology. 2018;106:162–170. https://doi.org/10.1007/s10266-017-0322-5.; Kashiwagi Y, Aburaya S, Sugiyama N, Narukawa Y, Sakamoto Y, Takahashi M et al. Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model. Sci Rep. 2021;11:18398. https://doi.org/10.1038/s41598-021-97868-2.; Usui M, Onizuka S, Sato T, Kokabu S, Ariyoshi W, Nakashima K. Mechanism of alveolar bone destruction in periodontitis – Periodontal bacteria and inflammation. Jpn Dent Sci Rev. 2021;57:201–208. https://doi.org/10.1016/j.jdsr.2021.09.005.; Hienz SA, Paliwal S, Ivanovski S. Mechanisms of Bone Resorption in Periodontitis. J Immunol Res. 2015;2015:615486. https://doi.org/10.1155/2015/615486.; Hascoët E, Blanchard F, Blin-Wakkach C, Guicheux J, Lesclous P, Cloitre A. New insights into inflammatory osteoclast precursors as therapeutic targets for rheumatoid arthritis and periodontitis. Bone Res. 2023;11(1):26. https://doi.org/10.1038/s41413-023-00257-w.; Saito A, Inagaki S, Kimizuka R, Okuda K, Hosaka Y, Nakagawa T, Ishihara K. Fusobacterium nucleatum enhances invasion of human gingival epithelial and aortic endothelial cells by Porphyromonas gingivalis. FEMS Immunol Med Microbiol. 2008;54:349–355. https://doi.org/10.1111/j.1574-695X.2008.00481.x.; Mei F, Xie M, Huang X, Long Y, Lu X, Wang X, Chen L. Porphyromonas gingivalis and Its Systemic Impact: Current Status. Pathogens. 2020;9(11):944. https://doi.org/10.3390/pathogens9110944.; Wegner N, Lundberg K, Kinloch A, Fisher B, Malmström V, Feldmann M, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233(1):34–54. https://doi.org/10.1111/j.0105-2896.2009.00850.x.; Krutyhołowa A, Strzelec K, Dziedzic A, Bereta GP, Łazarz-Bartyzel K, Potempa J. Host and bacterial factors linking periodontitis and rheumatoid arthritis. Front Immunol. 2022;13:980805. https://doi.org/10.3389/fimmu.2022.980805.; González-Febles J, Sanz M. Periodontitis and rheumatoid arthritis: What have we learned about their connection and their treatment? Periodontol 2000. 2021;87(1):181–203. https://doi.org/10.1111/prd.12385.; Koziel J, Mydel P, Potempa J. The link between periodontal disease and rheumatoid arthritis: an updated review. Curr Rheumatol Rep. 2014;16(3):408. https://doi.org/10.1007/s11926-014-0408-9.; Gabarrini G, Grasso S, van Winkelhoff AJ, van Dijl JM. Gingimaps: Protein Localization in the Oral Pathogen Porphyromonas gingivalis. Microbiol Mol Biol Rev. 2020;84(1):e00032–19. https://doi.org/10.1128/mmbr.00032-19.; Liao F, Li Z, Wang Y, Shi B, Gong Z, Cheng X. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitisassociated rheumatoid arthritis. Med Hypotheses. 2009;72(6):732–735. https://doi.org/10.1016/j.mehy.2008.12.040.; Maresz KJ, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 2013;9(9):e1003627. https://doi.org/10.1371/journal.ppat.1003627.; Reichert S, Haffner M, Keyßer G, Schäfer C, Stein JM, Schaller H-G et al. Detection of oral bacterial DNA in synovial fluid. J Clin Periodontol. 2013;40:591–598. https://doi.org/10.1111/jcpe.12102.; Totaro MC, Cattani P, Ria F, Tolusso B, Gremese E, Fedele AL et al. Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. Arthritis Res Ther. 2013;15:R66. https://doi.org/10.1186/ar4243.; Perricone C, Ceccarelli F, Saccucci M, Di Carlo G, Bogdanos DP, Lucchetti R et al. Porphyromonas gingivalis and rheumatoid arthritis. Curr Opin Rheumatol. 2019;31(5):517–524. https://doi.org/10.1097/BOR.0000000000000638.; Kini V, Mohanty I, Telang G, Vyas N. Immunopathogenesis and distinct role of Th17 in periodontitis: A review. J Oral Biosci. 2022;64(2):193–201. https://doi.org/10.1016/j.job.2022.04.005.; Li C, Yu R, Ding Y. Association between Porphyromonas Gingivalis and systemic diseases: Focus on T cells-mediated adaptive immunity. Front Cell Infect Microbiol. 2022;12:1026457. https://doi.org/10.3389/fcimb.2022.1026457.; Gómez-Bañuelos E, Mukherjee A, Darrah E, Andrade F. Rheumatoid arthritisassociated mechanisms of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. J Clin Med. 2019;8:1309. https://doi.org/10.3390/jcm8091309.; Möller B, Kollert F, Sculean A, Villiger PM. Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. Front Immunol. 2020;11:1108. https://doi.org/10.3389/fimmu.2020.01108.; Schwenzer A, Quirke AM, Marzeda AM, Wong A, Montgomery AB, Sayles HR et al. Association of Distinct Fine Specificities of Anti-Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis. Arthritis Rheumatol. 2017;69(12):2303–2313. https://doi.org/10.1002/art.40227.; Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. 2016;8(369):369ra176. https://doi.org/10.1126/scitranslmed.aaj1921.; Sakkas LI, Daoussis D, Liossis S-N, Bogdanos DP. The infectious basis of ACPA-positive rheumatoid arthritis. Front Microbiol. 2017;8:1853. https://doi.org/10.3389/fmicb.2017.01853.; Kulkarni A, Beckler MD, Amini SS, Kesselman MM. Oral Microbiome in PreRheumatoid Arthritis: The Role of Aggregatibacter Actinomycetemcomitans in Bacterial Composition. Cureus. 2022;14(12):e32201. https://doi.org/10.7759/cureus.32201.; Looh SC, Soo ZMP, Wong JJ, Yam HC, Chow SK, Hwang JS. Aggregatibacter actinomycetemcomitans as the Aetiological Cause of Rheumatoid Arthritis: What Are the Unsolved Puzzles? Toxins (Basel). 2022;14(1):50. https://doi.org/10.3390/toxins14010050.; Mukherjee A, Jantsch V, Khan R, Hartung W, Fischer R, Jantsch J et al. Rheumatoid Arthritis-Associated Autoimmunity Due to Aggregatibacter actinomycetemcomitans and Its Resolution With Antibiotic Therapy. Front Immunol. 2018;9:2352. https://doi.org/10.3389/fimmu.2018.02352.; Huang Y, Ni S. Aggregatibacter Actinomycetemcomitans With Periodontitis and Rheumatoid Arthritis. Int Dent J. 2024;74(1):58–65. https://doi.org/10.1016/j.identj.2023.06.011.; Gomez-Bañuelos E, Johansson L, Konig MF, Lundquist A, Paz M, Buhlin K et al. Exposure to Aggregatibacter actinomycetemcomitans before Symptom Onset and the Risk of Evolving to Rheumatoid Arthritis. J Clin Med. 2020;9(6):1906. https://doi.org/10.3390/jcm9061906.; Janssen KM, Vissink A, de Smit MJ, Westra J, Brouwer E. Lessons to be learned from periodontitis. Curr Opin Rheumatol. 2013;25(2):241–247. https://doi.org/10.1097/BOR.0b013e32835d833d.; Kaur S, White S, Bartold PM. Periodontal disease and rheumatoid arthritis: a systematic review. J Dent Res. 2013;92:399–408. https://doi.org/10.1177/0022034513483142.; Agnihotri R, Gaur S. Rheumatoid arthritis in the elderly and its relationship with periodontitis: a review. Geriatr Gerontol Int. 2014;14:8–22. https://doi.org/10.1111/ggi.12062.; Montgomery AB, Lugli EB, Venables PJ. Is citrullination the missing link between periodontal disease and rheumatoid arthritis? Curr Oral Health Rep. 2015;2:30–36. https://doi.org/10.1007/s40496-014-0042-7.; Mikuls TR, Payne JB, Deane KD, Thiele GM. Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: the spark that lights the fire in rheumatoid arthritis. J Allergy Clin Immunol. 2016;137:28–34. https://doi.org/10.1016/j.jaci.2015.10.024.; Bartold PM, Mariotti A. The future of periodontal-systemic associations: raising the standards. Curr Oral Health Rep. 2017;4:258–262. https://doi.org/10.1007/s40496-017-0150-2.; Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat Rev Immunol. 2021;21:426–440. https://doi.org/10.1038/s41577-020-00488-6.; Koziel J, Potempa J. Pros and cons of causative association between periodontitis and rheumatoid arthritis. Periodontol 2000. 2022;89:83–98. https://doi.org/10.1111/prd.12432.; Ahmadi P, Mahmoudi M, Kheder RK, Faraj TA, Mollazadeh S, Abdulabbas HS, Esmaeili SA. Impacts of Porphyromonas ingivalis periodontitis on rheumatoid arthritis autoimmunity. Int Immunopharmacol. 2023;118:109936. https://doi.org/10.1016/j.intimp.2023.109936.; Cheng Z, Meade J, Mankia K, Emery P, Devine DA. Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31(1):19–30. https://doi.org/10.1016/j.berh.2017.08.001.; Schmidt TS, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY et al. Extensive transmission of microbes along the gastrointestinal tract. Elife. 2019:8:e42693. https://doi.org/10.7554/eLife.42693.; Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquín AJ, Pizano-Zárate ML, García-Mena J, Ramírez-Durán N. Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis. J Immunol Res. 2017;2017:4835189. https://doi.org/10.1155/2017/4835189.; Krajewska-Włodarczyk M. The role of the human microbiom in the pathogenesis of rheumatoid arthritis – a literature review. Wiad Lek. 2017;70(4):798–803. Available at: https://wiadlek.pl/wp-content/uploads/2020/02/WL-4-2017.pdf.; Tan X, Wang Y, Gong T. The interplay between oral microbiota, gut microbiota and systematic diseases. J Oral Microbiol. 2023;15(1):2213112. https://doi.org/10.1080/20002297.2023.2213112.; Yamazaki K, Kamada N. Exploring the oral-gut linkage: Interrelationship between oral and systemic diseases. Mucosal Immunol. 2024;17(1):147–153. https://doi.org/10.1016/j.mucimm.2023.11.006.; Brandl C, Bucci L, Schett G, Zaiss MM. Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol. 2021;51(4):798–810. https://doi.org/10.1002/eji.202048876.; Симаненков ВИ, Маев ИВ, Ткачева ОН, Алексеенко СА. Андреев ДН, Бордин ДС и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. https://doi.org/10.15829/1728-8800-2021-2758.; Симаненков ВИ, Маев ИВ, Ткачева ОН, Алексеенко СА, Андреев ДН, Бакулина НВ и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022;94(8):6–22. https://doi.org/10.26442/00403660.2022.08.201523.; Berthelot JM, Bandiaky ON, Le Goff B, Amador G, Chaux AG, Soueidan A, Denis F. Another Look at the Contribution of Oral Microbiota to the Pathogenesis of Rheumatoid Arthritis: A Narrative Review. Microorganisms. 2021;10(1):59. https://doi.org/10.3390/microorganisms10010059.; Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol. 2021;12:673708. https://doi.org/10.3389/fimmu.2021.673708.; Picchianti-Diamanti A, Rosado MM, D’Amelio R. Infectious agents and inflammation: the role of microbiota in autoimmune arthritis. Front Microbiol. 2018;8:2696. https://doi.org/10.3389/fmicb.2017.02696.; Arimatsu K, Yamada H, Miyazawa H, Minagawa T, Nakajima M, Ryder MI et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4:4828. https://doi.org/10.1038/srep04828.; Kobayashi T, Iwaki M, Nakajima A, Nogami A, Yoneda M. Current research on the pathogenesis of NAFLD/NASH and the gut-liver axis: Gut microbiota, dysbiosis, and leaky-gut syndrome. Int J Mol Sci. 2022;23(19):11689. https://doi.org/10.3390/ijms231911689.; Xing T, Liu Y, Cheng H, Bai M, Chen J, Ji H et al. Ligature induced periodontitis in rats causes gut dysbiosis leading to hepatic injury through SCD1/ AMPK signalling pathway. Life Sci. 2022;288:120162. https://doi.org/10.1016/j.lfs.2021.120162.; Bao J, Li L, Zhang Y, Wang M, Chen F, Ge S et al. Periodontitis may induce gut microbiota dysbiosis via salivary microbiota. Int J Oral Sci. 2022;14:32. https://doi.org/10.1038/s41368-022-00183-3.; Chang Y, Chung MK, Park JH, Song TJ. Association of Oral Health with Risk of Rheumatoid Arthritis: A Nationwide Cohort Study. J Pers Med. 2023;13(2):340. https://doi.org/10.3390/jpm13020340.; Choi YY, Lee KH. Periodontitis as a risk factor for rheumatoid arthritis: a matched-cohort study. Int Dent J. 2021;71:516–521. https://doi.org/10.1016/j.identj.2021.01.006.; Chen H-H, Huang N, Chen Y-M, Chen T-J, Chou P, Lee Y-L et al. Association between a history of periodontitis and the risk of rheumatoid arthritis: a nationwide, population-based, case-control study. Ann Rheum Dis. 2013;72:1206–1211. https://doi.org/10.1136/annrheumdis-2012-201593.; Chou Y-Y, Lai K-L, Chen D-Y, Lin D-H, Chen H-H. Rheumatoid arthritis risk associated with periodontitis exposure: a nationalwide, population-based cohort study. PLoS ONE. 2015;10(10):e0139693. https://doi.org/10.1371/journal.pone.0139693.; Zhao X, Liu Z, Shu D, Xiong Y, He M, Xu S et al. Association of Periodontitis with Rheumatoid Arthritis and the Effect of Non-Surgical Periodontal Treatment on Disease Activity in Patients with Rheumatoid Arthritis. Med Sci Monit. 2018;24:5802–5810. https://doi.org/10.12659/MSM.909117.; Vahabi S, Rostamian A, Baniebrahimi G. Characteristics and relationship of periodontal disease with juvenile idiopathic and rheumatoid arthritis. Dent Res J (Isfahan). 2015;12(6):541–547. Available at: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4696356&blobtype=pdf.; Svärd A, Kastbom A, Ljungberg KR, Potempa B, Potempa J, Persson GR et al. Antibodies against Porphyromonas gingivalis in serum and saliva and their association with rheumatoid arthritis and periodontitis. Data from two rheumatoid arthritis cohorts in Sweden. Front Immunol. 2023;14:1183194. https://doi.org/10.3389/fimmu.2023.1183194.; Takeuchi-Hatanaka K, Koyama Y, Okamoto K, Sakaida K, Yamamoto T, Takashiba S. Treatment resistance of rheumatoid arthritis relates to infection of periodontal pathogenic bacteria: a case-control cross-sectional study. Sci Rep. 2022;12(1):12353. https://doi.org/10.1038/s41598-022-16279-z.; Moura MF, Cota LO, Costa AM, Silva TA, Costa FO. Rheumatoid arthritis associated with the occurrence, severity and extension of periodontitis: A case-control study. J Clin Exp Dent. 2021;13(4):e389–e396. https://doi.org/10.4317/jced.57540.; Bolstad AI, Fevang BS, Lie SA. Increased risk of periodontitis in patients with rheumatoid arthritis: A nationwide register study in Norway. J Clin Periodontol. 2023;50(8):1022–1032. https://doi.org/10.1111/jcpe.13826.; Choi IA, Kim J-H, Kim YM, Lee JY, Kim KH, Lee EY et al. Periodontitis is associated with rheumatoid arthritis: a study with longstanding rheumatoid arthritis patients in Korea. Korean J Intern Med. 2016;31:977–986. https://doi.org/10.3904/kjim.2015.202.; Äyräväinen L, Leirisalo-Repo M, Kuuliala A, Ahola K, Koivuniemi R, Meurman JH et al. Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. BMJ Open. 2017;7(1):e011916. https://doi.org/10.1136/bmjopen-2016-011916.; Rodríguez-Lozano B, González-Febles J, Garnier-Rodríguez JL, Dadlani S, Bustabad-Reyes S, Sanz M et al. Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case-control study. Arthritis Res Ther. 2019;21(1):27. https://doi.org/10.1186/s13075-019-1808-z.; Wolff B, Berger T, Frese C, Max R, Blank N, Lorenz H-M et al. Oral status in patients with early rheumatoid arthritis: a prospective, case-control study. Rheumatology (Oxford). 2014;53:526–531. https://doi.org/10.1093/rheumatology/ket362.; Nik-Azis NM, Mohd N, Baharin B, Said MSM, Fadzilah FM, Haflah NHM. Periodontal disease in seropositive rheumatoid arthritis: scoping review of the epidemiological evidence. Germs. 2021;11(2):266–286. https://doi.org/10.18683/germs.2021.1263.; Cheng Z, Gao L, Huang P, Luo D, Bi C, Chen X. Genetic causal association between rheumatoid arthritis and periodontitis: a bidirectional two-sample Mendelian randomization analysis. Clin Oral Investig. 2024;28(1):107. https://doi.org/10.1007/s00784-024-05512-w.; Fuggle NR, Smith TO, Kaul A, Sofat N. Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis. Front Immunol. 2016;7:80. https://doi.org/10.3389/fimmu.2016.00080.; Qiao Y, Wang Z, Li Y, Han Y, Zhou Y, Cao X. Rheumatoid arthritis risk in periodontitis patients: A systematic review and meta-analysis. Joint Bone Spine. 2020;87(6):556–564. https://doi.org/10.1016/j.jbspin.2020.04.024.; de Oliveira Ferreira R, de Brito Silva R, Magno MB, Carvalho Almeida APCPS, Fagundes NCF, Maia LC, Lima RR. Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19858514. https://doi.org/10.1177/1759720X19858514.; Eezammuddeen NN, Vaithilingam RD, Hassan NHM. Influence of periodontitis on levels of autoantibodies in rheumatoid arthritis patients: A systematic review. J Periodontal Res. 2023;58(1):29–42. https://doi.org/10.1111/jre.13065.; Moradi F, Shamsoddin E. Is periodontitis associated with the risk of immunemediated systemic conditions? Evid Based Dent. 2023;24(2):83–84. https://doi.org/10.1038/s41432-023-00903-6.; Larvin H, Kang J, Aggarwal VR, Pavitt S, Wu J. Periodontitis and risk of immune-mediated systemic conditions: A systematic review and meta-analysis. Community Dent Oral Epidemiol. 2023;51(5):705–717. https://doi.org/10.1111/cdoe.12812.; Bender P, Bürgin WB, Sculean A, Eick S. Serum antibody levels against Porphyromonas gingivalis in patients with and without rheumatoid arthritis - a systematic review and meta-analysis. Clin Oral Investig. 2017;21(1):33–42. https://doi.org/10.1007/s00784-016-1938-5.; Li Y, Guo R, Oduro PK, Sun T, Chen H, Yi Y et al. The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis. Front Cell Infect Microbiol. 2022;12:956417. https://doi.org/10.3389/fcimb.2022.956417.; Wen S, Beltrán V, Chaparro A, Espinoza F, Riedemann JP. Association between chronic periodontitis and rheumatoid arthritis. A systematic review. Rev Med Chil. 2019;147(6):762–775. https://doi.org/10.4067/S0034-98872019000600762.; Kaur S, Bright R, Proudman SM, Bartold PM. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):113–122. https://doi.org/10.1016/j.semarthrit.2014.04.009.; Cosgarea R, Tristiu R, Dumitru RB, Arweiler NB, Rednic S, Sirbu CI et al. Effects of non-surgical periodontal therapy on periodontal laboratory and clinical data as well as on disease activity in patients with rheumatoid arthritis. Clin Oral Investig. 2019;23(1):141–151. https://doi.org/10.1007/s00784-018-2420-3.; Khare N, Vanza B, Sagar D, Saurav K, Chauhan R, Mishra S. Nonsurgical Periodontal Therapy decreases the Severity of Rheumatoid Arthritis: A Case-control Study. J Contemp Dent Pract. 2016;17(6):484–488. https://doi.org/10.5005/jp-journals-10024-1877.; Silvestre FJ, Silvestre-Rangil J, Bagán L, Bagán JV. Effect of nonsurgical periodontal treatment in patients with periodontitis and rheumatoid arthritis: A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21(3):e349–e354. https://doi.org/10.4317/medoral.20974.; Inchingolo F, Inchingolo AM, Avantario P, Settanni V, Fatone MC, Piras F et al. The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodontitis: A Systematic Review. Int J Mol Sci. 2023;24(24):17228. https://doi.org/10.3390/ijms242417228.; Zhang J, Xu C, Gao L, Zhang D, Li C, Liu J. Influence of anti-rheumatic agents on the periodontal condition of patients with rheumatoid arthritis and periodontitis: A systematic review and meta-analysis. J Periodontal Res. 2021;56(6):1099–1115. https://doi.org/10.1111/jre.12925.; Mustufvi Z, Twigg J, Kerry J, Chesterman J, Pavitt S, Tugnait A, Mankia K. Does periodontal treatment improve rheumatoid arthritis disease activity? A systematic review. Rheumatol Adv Pract. 2022;6(2):rkac061. https://doi.org/10.1093/rap/rkac061.; Atarbashi-Moghadam F, Rashidi Maybodi F, Dehghan A, Haerian Ardakani A. Effect of non-surgical periodontal treatment on clinical signs of rheumatoid arthritis. J Adv Periodontol Implant Dent. 2018;10(1):13–17. Available at: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9327444&blobtype=pdf.; Calderaro DC, Corrêa JD, Ferreira GA, Barbosa IG, Martins CC, Silva TA, Teixeira AL. Influence of periodontal treatment on rheumatoid arthritis: a systematic review and meta-analysis. Rev Bras Reumatol Engl Ed. 2017;57(3):238–244. https://doi.org/10.1016/j.rbre.2016.11.011.; Silvestre F-J, Silvestre-Rangil J, Bagán L, Bagán JV. Effect of nonsurgical periodontal treatment in patients with rheumatoid arthritis: a systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e349–e354. https://doi.org/10.4317/medoral.20974.; Del Rei Daltro Rosa CD, de Luna Gomes JM, Dantas de Moraes SL, Araujo Lemos CA, Minatel L, Justino de Oliveira Limirio JP, Pellizzer EP. Does non-surgical periodontal treatment influence on rheumatoid arthritis? A systematic review and meta-analysis. Saudi Dent J. 2021;33(8):795–804. https://doi.org/10.1016/j.sdentj.2021.09.007.; Sun J, Zheng Y, Bian X, Ge H, Wang J, Zhang Z. Non-surgical periodontal treatment improves rheumatoid arthritis disease activity: a meta-analysis. Clin Oral Investig. 2021;25(8):4975–4985. https://doi.org/10.1007/s00784-021-03807-w.; Hashimoto H, Hashimoto S, Shimazaki Y. Association between the extent of periodontal inflammation and the severity of rheumatoid arthritis in Japanese patients with rheumatoid arthritis. Int Dent J. 2021;71:429–437. https://doi.org/10.1016/j.identj.2020.12.015.; Falcao A, Bullón P. A review of the influence of periodontal treatment in systemic diseases. Periodontol 2000. 2019;79(1):117–128. https://doi.org/10.1111/prd.12249.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8250

Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation ; Клинико-иммунологические варианты АНЦА-ассоциированного системного васкулита: в фокусе интерстициальный фиброз легких при микроскопическом полиангиите с гиперпродукцией антител к миелопероксидазе и ревматоидного фактора. Собственное наблюдение и обзор литературы

Συγγραφείς: T. V. Beketova, O. A. Golovina, A. S. Avdeeva, Т. В. Бекетова, О. А. Головина, А. С. Авдеева

Πηγή: Rheumatology Science and Practice; Vol 61, No 1 (2023); 62-69 ; Научно-практическая ревматология; Vol 61, No 1 (2023); 62-69 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, microscopic polyangiitis, anti-myeloperoxidase antibody, pulmonary fibrosis, rheumatoid arthritis, rheumatoid factor, antibodies to cyclic citrullinated peptide, микроскопический полиангиит, антитела к миелопероксидазе, интерстициальный фиброз легких, ревматоидный артрит, ревматоидный фактор

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3279/2259; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi:10.1002/art.37715; Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi:10.1002/art.34562; Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCAassociated vasculitis – Clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570-579. doi:10.1038/nrrheum.2016.123; Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908-2918. doi:10.1002/art.23800; Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;90(5):13-21. doi:10.26442/terarkh201890513-21; Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65(6):847-856. doi:10.1016/s0025-6196(12)62575-0; Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9(2):190-196. doi:10.1111/j.1440-1843.2004.00581.x; Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: Analysis of 17 patients. Respir Med. 2008;102(10):1392-1398. doi:10.1016/j.rmed.2008.04.023; Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration. 2009;77(4):407-415. doi:10.1159/000183754; Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al.; French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68(3):404-407. doi:10.1136/ard.2008.096131; Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36(1):116-121. doi:10.1183/09031936.00110109; Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93(24):340-349. doi:10.1097/MD.0000000000000217; Huang H, Wang YX, Jiang CG, Liu J, Li J, Xu K, et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med. 2014;14:8. doi:10.1186/1471-2466-14-8; Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):e000058. doi:10.1136/bmjresp-2014-000058; Flores-Suárez LF, Ruiz N, Saldarriaga Rivera LM, Pensado L. Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre. Clin Rheumatol. 2015;34(9):1653-1654. doi:10.1007/s10067-015-2967-1; Watanabe T, Minezawa T, Hasegawa M, Goto Y, Okamura T, Sakakibara Y, et al. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: A retrospective single-center study. BMC Pulm Med. 2019;19(1):194. doi:10.1186/s12890-019-0969-5; Захарова EB, Яковлев BH, Виноградова OB, Шейх ЖВ, Жидкова НВ, Алексеев ВГ. ANCA-ассоциированные васкулиты с поражением легких и почек: клинико-морфологическая характеристика, лечение, исходы. Клиническая медицина. 2013;91(7):38-43.; Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608-615. doi:10.1016/j.rmed.2013.01.006; Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16(7):722-729. doi:10.1016/j.autrev.2017.05.008; Moon JS, Lee DD, Park YB, Lee SW. Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clin Rheum. 2018;37(10):2771-2779. doi:10.1007/s10067-017-3902-4; Фролова НФ, Корсакова ЛВ, Столяревич ЕС, Бекетова ТВ. Дебют АНЦА-ассоциированного системного васкулита под маской ревматоидного артрита. Научно-практическая ревматология. 2015;53(6):653-656. doi:10.14412/1995-4484-2015-633-656; Pagnoux C, Seror R, Bérezné A, Rouabhia S, Goulvestre C, Guillevin L. Remittent non-destructive polysynovitis in P-ANCApositive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604-607. doi:10.1016/j.jbspin.2010.02.013; Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol. 2005;24(6):673-676. doi:10.1007/s10067-005-1104-y; Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibodyassociated vasculitis. BMC Immunol. 2017;18(1):53. doi:10.1186/s12865-017-0234-8; Nathani D, Barnett MH, Spies J, Pollard J, Wang MX, Kiernan MC. Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. Muscle Nerve. 2019;59(6):643-649. doi:10.1002/mus.26431; Martín-Nares E, Zuñiga-Tamayo D, Hinojosa-Azaola A. Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: An unrecognized example of poliautoimmunity. Clin Rheumatol. 2019;38(1):97-106. doi:10.1007/s10067-018-4212-1; Kısacık B, Önder ME, Sayarlıoğlu M, Onat AM. Symmetric polyarthritis as an initial symptom in granulomatosis with polyangiitis: A report of six cases and review of the literature. Eur J Rheum. 2018;5(3):191-193. doi:10.5152/eurjrheum.2018.17050; Holle JU, Herrmann K, Gross WL, Csernok E. Comparative analy sis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):66-69.; Kallenberg CG. Key advances in the clinical approach to ANCAassociated vasculitis. Nat Rev Rheumatol. 2014;10(8):484-493. doi:10.1038/nrrheum.2014.104; Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol. 1996;23(5):826-830.; Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Antimyeloperoxidase antibodies in patients with rheumatoid arthritis: Prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis. 1994;53(1):24-29. doi:10.1136/ard.53.1.24; Al-Rubaye M. Anti-neutrophlic cytoplasmic antibody elastase, lactoferrin, cathapsin G, and lysozyme in a sample of Iraqi patients with rheumatoid arthritis. Journal of the Faculty of Medicine Baghdad. 2015;57(1):68-74. doi:10.32007/jfacmedbagdad.571312; Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis. 2000;59(11):898-903. doi:10.1136/ard.59.11.898; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;(5):33-46 doi:10.1155/2013/726598; van Schaardenburg D, Lagaay AM, Breedveld FC, Hijmans W, Vandenbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol. 1993;32(2):104-109. doi:10.1093/rheumatology/32.2.104; Shillitoe EJ, Lehner T, Lessof MH, Harrison DF. Immunological features of Wegener’s granulomatosis. Lancet. 1974;1(7852):281-284. doi:10.1016/s0140-6736(74)92594-x; Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71-79. doi:10.1093/rheumatology/kev286; McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in antineutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-247. doi:10.2215/CJN.05610611; Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi:10.14412/1995-4484-2019-3-40; Hoffmann-Vold AM, Maher TM, Philpot EP, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2): 71-83. doi:10.1016/S2665-9913(19)30144-4; Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-436. doi:10.1016/j.semarthrit.2014.09.002; Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353-359. doi:10.1111/resp.12214; Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34(Suppl 100(5)):181-185.; Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7; Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-1008. doi:10.1093/rheumatology/kei211; Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. doi:10.3899/jrheum.121043; Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681; Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3. doi:10.1186/s12890-019-1030-4; Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076; Ананьева ЛП, Авдеев СН, Тюрин ИЕ, Лила АМ, Загребнева АИ, Маслянский АЛ, и др. Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фенотипом. Научно-практическая ревматология. 2020;58(6): 631-636. doi:10.47360/1995-4484-2020-631-636

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3279
https://doi.org/10.47360/1995-4484-2023-62-69

Peculiarities of immunological manifestations in patients with rheumatoid arthritis in the presence of chronic infection with Helicobacter pylori variant encoding cytotoxin-associated gene A ; Особенности иммунологических проявлений у пациентов с ревматоидным артритом при наличии хронического инфицирования штаммом Helicobacter pylori, кодирующим ассоциированный с цитотоксином ген A

Συγγραφείς: A. V. Aleksandrov, L. N. Shilova, V. A. Aleksandrov, M. V. Levkina, O. V. Paramonova, N. V. Aleksandrova, I. A. Zborovskaya, А. В. Александров, Л. Н. Шилова, В. А. Александров, М. В. Левкина, О. В. Парамонова, Н. В. Александрова, И. А. Зборовская

Πηγή: Medical Immunology (Russia); Том 25, № 4 (2023); 927-932 ; Медицинская иммунология; Том 25, № 4 (2023); 927-932 ; 2313-741X ; 1563-0625

Θεματικοί όροι: белок CagA, antibodies to cyclic citrullinated peptide, infection, diagnostics, Helicobacter pylori, CagA protein, антитела к циклическому цитруллинированному пептиду, инфекция, диагностика, хеликобактер пилори

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2702/1804; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11049; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11050; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11051; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11052; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11053; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11081; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11082; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11083; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11084; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2702/11095; Bartels L.E., Pedersen A.B., Kristensen N.R., Jepsen P., Vilstrup H., Stengaard-Pedersen K., Dahlerup J.F. Helicobacter pylori infection is not associated with rheumatoid arthritis. Scand. J. Rheumatol., 2019, Vol. 48, pp. 24-31.; Ebrahimi A., Soofizadeh B., Ebrahimi F., Moaadab S.Y., Bonyadi M., Gojazadeh M., Malek Mahdavi A. Relationship between Helicobacter pylori cytotoxin-associated gene A protein with clinical outcomes in patients with rheumatoid arthritis. Immunol. Lett., 2019, Vol. 211, pp. 49-52.; Elbehiry A., Marzouk E., Aldubaib M., Abalkhail A., Anagreyyah S., Anajirih N., Almuzaini A.M., Rawway M., Alfadhel A., Draz A., Abu-Okail A. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics (Basel), 2023, Vol. 12, no. 2, 191. doi:10.3390/antibiotics12020191.; Etchegaray-Morales I., Jiménez-Herrera E.A., Mendoza-Pinto C., Rojas-Villarraga A., Macías-Díaz S., Osorio-Peña Á.D., Munguía-Realpozo P., García-Carrasco M. Helicobacter pylori and its association with autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis and Sjögren syndrome. J. Transl. Autoimmun., 2021, Vol. 4, 100135. doi:10.1016/j.jtauto.2021.100135.; Gadieva Sh.F., Musaev S.K. Impact of clinical and immunological parameters on the frequency and prevalence of Helicobacter pylori in patients with rheumatoid arthritis. Rheumatology Science and Practice, 2017, Vol. 55, no. 6, pp. 634-636. (In Russ.); Ju H., Brasier A.R., Kurosky A., Xu B., Reyes V.E., Graham D.Y. Diagnostics for statistical variable selection methods for prediction of peptic ulcer disease in Helicobacter pylori infection. J. Proteomics Bioinform., 2014, Vol. 7, no. 4, 1000307. doi:10.4172/jpb.1000308.; Karbalaei M., Talebi Bezmin Abadi A., Keikha M. Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis. BMC Infect. Dis., 2022, Vol. 22, no. 1, 573. doi:10.1186/s12879-022-07546-5.; Kastbom A., Roos Ljungberg K., Ziegelasch M., Wettero J., Skogh T., Martinsson K. Changes in anticitrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis. Clin. Exp. Immunol., 2018, Vol. 194, no. 3, pp. 391-399.; Nguyen Q.A., Schmitt L., Mejías-Luque R., Gerhard M. Effects of Helicobacter pylori adhesin HopQ binding to CEACAM receptors in the human stomach. Front. Immunol., 2023, Vol. 14, 1113478. doi:10.3389/fimmu.2023.1113478.; Sijmons D., Guy A.J., Walduck A.K., Ramsland P.A. Helicobacter pylori and the role of lipopolysaccharide variation in innate immune evasion. Front. Immunol., 2022, Vol. 13, 868225. doi:10.3389/fimmu.2022.868225.; Tian Y., Russo R.M., Li Y, Karmakar M., Liu B., Puskarich M.A., Jones A.E., Stringer K.A., Standiford T.J., Alam H.B. Serum citrullinated histone H3 concentrations differentiate patients with septic verses non-septic shock and correlate with disease severity. Infection, 2021, Vol. 49, no. 1, pp. 83-93.; Traby L., Kollars M., Kussmann M., Karer M., Šinkovec H., Lobmeyr E., Hermann A., Staudinger T., Schellongowski P., Rössler B., Burgmann H., Kyrle P.A., Eichinger S. Extracellular vesicles and citrullinated histone H3 in coronavirus disease 2019 patients. Thromb. Haemost., 2022, Vol. 122, no. 1, pp. 113-122.; Wang L., Cao Z.M., Zhang L.L., Dai X.C., Liu Z.J., Zeng Y.X., Li X.Y., Wu Q.J., Ly W.L. Helicobacter pylori and Autoimmune Diseases: Involving Multiple Systems. Front. Immunol., 2022, Vol. 13, 833424. doi:10.3389/fimmu.2022.833424.; Youssefi M., Tafaghodi M., Farsiani H., Ghazvini K., Keikha M. Helicobacter pylori infection and autoimmune diseases; Is there an association with systemic lupus erythematosus, rheumatoid arthritis, autoimmune atrophy gastritis and autoimmune pancreatitis? A systematic review and meta-analysis study. J. Microbiol. Immunol. Infect., 2021, Vol. 54, pp. 359-369.; https://www.mimmun.ru/mimmun/article/view/2702

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/2702
https://doi.org/10.15789/1563-0625-POI-2702

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis ; Цереброваскулярная реактивность у пациентов с сочетанием ревматоидного артрита и артериальной гипертензии

Συγγραφείς: N. V. Rebrova, O. L. Sarkisova, T. M. Ripp, R. S. Karpov, V. F. Mordovin, Н. В. Реброва, О. Л. Саркисова, Т. М. Рипп, Р. С. Карпов, В. Ф. Мордовин

Πηγή: Rheumatology Science and Practice; Vol 60, No 3 (2022); 369-373 ; Научно-практическая ревматология; Vol 60, No 3 (2022); 369-373 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, rheumatoid arthritis, hypertension, rheumatoid factor, anti-citrullinated protein antibody, ревматоидный артрит, артериальная гипертензия, ревматоидный фактор

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3186/2200; Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: A systematic review and meta-analysis. Stroke. 2016;47(4):943-950. doi:10.1161/STROKEAHA.115.012052; Chen YR, Hsieh FI, Lien LM, Hu CJ, Jeng JS, Peng GS, et al. Rheumatoid arthritis significantly increased recurrence risk after ischemic stroke/transient ischemic attack. J Neurol. 2018;265(8):1810-1818. doi:10.1007/s00415-018-8885-9; Куликов ВП. Артериовенозная церебральная реактивность на гиперкапнию в диагностике нарушений мозгового кровотока. Клиническая физиология кровообращения. 2009;(4):5-15.; Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol. 2013;304(12):H1598-H1614. doi:10.1152/ajpheart.00490.2012; Liu M, Zhou L. Cerebrovascular reserve may be a more accurate predictor of stroke than degree of ICA or MCA stenosis. Med Sci Monit. 2014;20:2082-2087. doi:10.12659/MSM.892377; Новикова ДС, Попкова ТВ, Насонов ЕЛ. Артериальная гипертензия при ревматоидном артрите. Научно-практическая ревматология. 2011;49(3):52-68. doi:10.14412/1995-4484-2011-574; Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(5):724-725. doi:10.1136/ard.2007.073718; Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69(9):1649-1654. doi:10.1136/ard.2009.110536; López-Longo FJ, Oliver-Miñarro D, de la Torre I, GonzálezDíaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(4):419-424. doi:10.1002/art.24390; Hjeltnes G, Hollan I, Førre Ø, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: Predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40(6):422-427. doi:10.3109/03009742.2011.585350; Реброва НВ, Анисимова ЕА, Саркисова ОЛ, Мордовин ВФ, Карпов РС, Рипп ТМ, и др. Реактивность сосудов головного мозга у больных ревматоидным артритом в сочетании с артериальной гипертонией и без нее. Терапевтический архив. 2015;87(4):24-29.; Кривенко ЛЕ, Кузьменко ЕА, Вуд ТГ, Шерстнева ЕП. Оценка цереброваскулярной реактивности и функционального резерва мозгового кровообращения по данным функциональных проб у больных гипертонической болезнью. Дальневосточный медицинский журнал. 2013;1:9-13.; Рипп ТМ, Мордовин ВФ, Рипп ЕГ, Реброва НВ, Семке ГВ, Пекарский СЕ, и др. Комплексная оценка параметров цереброваскулярной реактивности. Сибирский журнал клинической и экспериментальной медицины. 2016;31(1):12-17. doi:10.29001/2073-8552-2016-31-1-12-17; Мошнина МА. Генетика ревматоидного артрита. Научнопрактическая ревматология. 2005;43(4):62-68. doi:10.14412/1995-4484-2005-620; Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(2):115-117.; Шилкина НП, Спирин НН, Юнонин ИЕ, Виноградов АА. Мозговая перфузия, артериальная гипертензия и эндотелиальная дисфункция при ревматоидном артрите. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(3-2):68- 75. doi:10.17116/jnevro201911903268; Poggesi A, Pasi M, Pescini F, Pantoni L, Inzitari D. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review. J Cereb Blood Flow Metab. 2016;36(1):72-94. doi:10.1038/jcbfm.2015.116; England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ. 2018;361:k1036. doi:10.1136/bmj.k1036; Navarro-Millán I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987; Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P. Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? J Cardiovasc Dis Res. 2013;4(2):102-106. doi:10.1016/j.jcdr.2012.09.003

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3186
https://doi.org/10.47360/1995-4484-2022-369-373

Seropositive juvenile rheumatoid arthritis: analysis of the spectrum of clinical manifestations and therapy according to a retrospective study ; Серопозитивный ювенильный ревматоидный артрит: анализ спектра клинических проявлений и терапии, по данным ретроспективного исследования

Συγγραφείς: М. I. Kaleda, I. P. Nikishina, E. S. Fedorov, S. V. Arsenyeva, A. N. Shapovalenko, М. И. Каледа, И. П. Никишина, Е. С. Федоров, С. В. Арсеньева, А. Н. Шаповаленко

Πηγή: Modern Rheumatology Journal; Том 15, № 1 (2021); 20-26 ; Современная ревматология; Том 15, № 1 (2021); 20-26 ; 2310-158X ; 1996-7012

Θεματικοί όροι: дети, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, methotrexate, children, ревматоидный фактор, антитела к циклическому цитруллинированному пептиду, метотрексат

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1095/1052; https://mrj.ima-press.net/mrj/article/view/1095/1060; Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. Philadelphia: Elsiever Saunders; 2016. P. 223-7.; Алексеева ЕИ. Ювенильный идиопатический артрит: клиническая картина, диагностика, лечение. Вопросы современной педиатрии. 2015;14(1):78-94.; Oliveira S, Ravelli A, Pistorio АМ, et al. Proxy-reported healthrelated quality of life of patients with juvenile rheumatoid arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007 Feb 15;57(1):35-43. doi:10.1002/art.22473.; Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-34. doi:10.1002/acr.23870. Epub 2019 Apr 25.; Oliveira-Ramos F, Eusebio M, Martins FM, et al. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016 Sep 22; 2(2):e000304. doi:10.1136/rmdopen-2016-000304. eCollection 2016.; Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012 Jun;64(6):2012-21. doi:10.1002/art.34343. Epub 2011 Dec 19.; Jia J, Li J, Yao X, et al. Genetic architecture study of rheumatoid arthritis and juvenile idiopathic arthritis. PeerJ. 2020 Jan 15;8:e8234. doi:10.7717/peerj.8234. eCollection 2020.; Насонов ЕЛ, Лила АМ. Ревматоидный артрит: достижения и нерешенные проблемы. Терапевтический архив. 2019; 91(5):4-7.; Mahmud SA, Binstadt BA. Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis. Front Immunol. 2019 Jan 14;9:3168. doi:10.3389/fimmu.2018.03168. eCollection 2018.; Lipinska J, Lipinska S, Kasielski M, Smolewska E. Anti-MCV and anti-CCP antibodies-diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA). Clin Rheumatol. 2016 Nov;35(11): 2699-706. doi:10.1007/s10067-016-3355-1. Epub 2016 Jul 25.; Harrold LR, Salman C, Shoor S, et al. Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996–2009. J Rheumatol. 2013 Jul;40(7):1218-25. doi:10.3899/jrheum.120661. Epub 2013 Apr 15.; Berthold E, Mansson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019 Oct 28;21(1):218. doi:10.1186/s13075-019-1994-8.; Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019 Feb;46(2):190-7. doi:10.3899/jrheum.180168. Epub 2018 Oct 1.; Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide populationbased study. Rheumatology (Oxford). 2017 Jun 1;56(6):928-933. doi:10.1093/rheumatology/kew500.; Van Rossum M, van Soesbergen R, de Kort S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol. 2003 Apr;30(4):825-8.; Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014 Aug;73(8):1487-94. doi:10.1136/annrheumdis-2012-203160. Epub 2013 May 28.; Sparchez M, Miu N, Bolba C, et al. Evaluation of anti-cyclic citrullinated peptide antibodies may be beneficial in RF-negative juvenile idiopathic arthritis patients. Clin Rheumatol. 2016 Mar;35(3):601-7. doi:10.1007/s10067-015-2971-5. Epub 2015 May 21.; Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother. Jul-Sep 2017;8(3):81-6. doi:10.4103/jpp.JPP_194_16.; Athreya BH, Doughty RA, Bookspan M, et al. Pulmonary manifestations of juvenile rheumatoid arthritis: a report of eight cases and review. Clin Chest Med. 1980 Sep; 1(3):361-74.; Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015 Oct;74(10): 1854-60. doi:10.1136/annrheumdis-2014-205372. Epub 2014 May 19.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1095
https://doi.org/10.14412/1996-7012-2021-1-20-26

CLINICAL CHARACTERISTICS OF THREE COHORTS OF PATIENTS WITH EARLY- AND LATE-ONSET RHEUMATOID ARTHRITIS (AT 50 YEARS OR OLDER). GENERALIZATION OF 40 YEARS’ EXPERIENCE ; Клиническая характеристика трех когорт раннего ревматоидного артрита с поздним началом (в возрасте 50 лет и старше). Обобщение 40-летнего опыта

Συγγραφείς: A. M. Satybaldyev, N. V. Demidova, G. I. Gridneva, N. Yu. Nikishina, E. V. Gerasimova, D. A. Gukasian, K. A. Kasumova, E. L. Luchikhina, A. S. Misiyuk, T. G. Oskilko, O. A. Rumyantseva, E. A. Zlepko, L. N. Tyurina, E. V. Fedorenko, N. V. Shornikova, E. L. Nasonov, А. М. Сатыбалдыев, Н. В. Демидова, Г. И. Гриднева, Н. Ю. Никишина, Е. В. Герасимова, Д. А. Гукасян, К. А. Касумова, Е. Л. Лучихина, А. С. Мисиюк, Т. Г. Оскилко, О. А. Румянцева, Е. А. Злепко, Л. Н. Тюрина, Е. В. Федоренко, Н. В. Шорникова, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 58, No 2 (2020); 140-146 ; Научно-практическая ревматология; Vol 58, No 2 (2020); 140-146 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: Общероссийский регистр больных ревматоидным артритом (ОРЕЛ), older age periods, classification criteria for rheumatoid arthritis, rheumatoid factor, anticyclic citrullinated peptide antibodies, DAS28, functional class, OREL All-Russian register of rheumatoid arthritis patients, старшие возрастные периоды, классификационные критерии ревматоидного артрита, ревматоидный фактор, антитела к циклическому цитруллинированному пептиду, функциональный класс

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2868/1945; McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19. doi:10.1056/NEJMra1004965; Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72. doi:10.1002/art.1780270805; Van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with «second-line» antirheumatic drugs: a randomized, controlled trial. Ann Intern Med. 1996;124:699-707. doi:10.7326/0003-4819-124-8-199604150-00001; Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26:S35-S61.; Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather then ant-CCP positivity, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis. Rheumatology. 2009;48(5):1557-9. doi:10.1093/rheumatology/kep314; Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094-108. doi:10.1016/S0140-6736(10)60826-4; Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum. 2011;40:371-88. doi:10.1016/j.semarthrit.2010.10.004; Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797-808. doi:10.7326/0003-4819-146-11-200706050-; Calvo-Alen J, Corrales A, Sanchez-Andrada S, et al. Outcome of late-onset rheumatoid arthritis. Clin Rheumatol. 2005;24:485-9. doi:10.1007/s10067-004-1067-4.13; Bukhari M, Lunt M, Barton A, et al. Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Ann Rheum Dis. 2007;66:389-93. doi:10.1136/ard.2006.055657; Radovits BJ, Fransen J, Eijsbouts A, et al. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:906-10. doi:10.1093/rheumatology/kep12; Innala L, Berglin E, Mü ller B, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16:R94. doi:10.1186/ar4540; Oka M, Kytila J. Rheumatoid arthritis with the onset in old age. Acta Rheumatol Scand. 1957;3:249-58. doi:10.3109/rhe1.1957.3.issue-1-4.28; Adler E. Rheumatoid arthritis in old age. Isr J Med Sci. 1966;2:607-13.; Ehrlich GE, Katz WA, Cohen SH. Rheumatoid arthritis in the aged. Geriatrics. 1970;25:103-13.; Corrigan AB, Robinson RG, Terenty TR, et al Benign rheumatoid arthritis of the aged. Br Med J. 1974;1:444-6. doi:10.1136/bmj.1.5905.444; MacGregor AJ. Classification criteria for rheumatoid arthritis. Baillieres Clin Rheumatol. 1995 May;9(2):287-304. doi:10.1016/S0950-3579(05)80191-8; Arnett FC, Edworthy SM, Bloch DA, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. doi:10.1002/art.1780310302; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8. doi:10.1136/ard.2010.138461; Ferraccioli GF, Cavalieri F, Mercadanti M, et al Clinical features, scintiscan characteristics and X-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol. 1984;2:157-61.; Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford). 1999;38:228-34. doi:10.1093/rheumatology/38.3.228; Van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol. 1991;18:1285-9.; Сатыбалдыев AM. Клинико-иммунологическая характеристика ревматоидного артрита, начавшегося в пожилом возрасте. Вопросы ревматизма. 1980;20(3):22-5.; Alpizar-Rodriguez D, Pluchino N, Canny G, et al. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology (Oxford). 2017 Aug;56(8):1254-63. doi:10.1093/rheumatology/kew318; Сатыбалдыев АМ. Ревматоидный артрит у пожилых. Consilium Medicum. 2007;12:85-92.; Arnold MB, Bykerk VP, Boire G, et al; on behalf of CATCH Investigators. Are there differences between young- and olderonset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology. 2014 Jun;53(6):1075-86. doi:10.1093/rheumatology/ket 449

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2868
https://doi.org/10.14412/1995-4484-2020-140-146

CLINICAL IMPORTANCE OF DETERMINATION OF HLA-DRB1 LOCUS GENES IN RHEUMATOID ARTHRITIS ; КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ОПРЕДЕЛЕНИЯ ГЕНОВ ЛОКУСА HLA-DRB1 ПРИ РЕВМАТОИДНОМ АРТРИТЕ

Συγγραφείς: V. Guseva, S. Lapin, V. Myachikova, A. Maslyanski, A. Chuchlovin, N. Ivanova, O. Tkachenko, T. Blinova, A. Totolian, В. И. Гусева, С. В. Лапин, В. Ю. Мячикова, А. Л. Маслянский, А. Б. Чухловин, Н. Е. Иванова, О. Ю. Ткаченко, Т. В. Блинова, А. А. Тотолян

Συνεισφορές: Исследование было поддержано грантом Российского научного фонда Соглашение РНФ № 16-15-00118.

Πηγή: Medical Immunology (Russia); Том 21, № 2 (2019); 333-340 ; Медицинская иммунология; Том 21, № 2 (2019); 333-340 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2019-2

Θεματικοί όροι: HLA-DRB1, antibodies to cyclic citrullinated peptide, smoking, антитела к циклическому цитруллинированному пептиду, курение

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2019-21-2-15/1133; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3473; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3474; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3475; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3476; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3477; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3478; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3479; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3480; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3481; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3482; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3483; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3484; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3550; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2019-21-2-15/3551; Беляева И.Б., Лапин С.В., Созина А.В., Мазуров В.И., Тотолян А.А. Антитела к цитруллин-содержащим антигенам в диагностике и прогнозировании течения раннего ревматоидного артрита // Медицинская иммунология, 2007. Т. 9, № 1. С. 77-84. [Belyaeva I.B., Lapin S.V., Sozina A.V., Mazurov V.I., Totolian Areg A. Autoantibodies to cirtullinated antigens for diagnosis and prediction of clinical course in early rheumatoid arthritis. Meditsinskaya immunologiya = Medical Immunology (Russia), 2007, Vol. 9, no. 1, pp. 77-84. (In Russ.)] doi:10.15789/1563-0625-2007-1-77-84.; Лапин С.В., Маслянский А.Л., Иливанова Е.П., Мазуров В.И., Тотолян А.А. Клиническое значение антител к циклическому цитруллинированному пептиду при раннем ревматоидном артрите // Медицинская иммунология, 2004. Т. 6, № 1-2. С. 57-66. [Lapin S.V., Maslyansky A.L., Ilivanova E.P., Mazurov V.I., Totolian A.A. Clinical significance of anti1cyclic citrullinated peptide (CCP) antibodies in patients with early rheumatoid arthritis. Meditsinskaya immunologiya = Medical Immunology (Russia), 2004, Vol. 6, no. 1-2, pp. 57-66. (In Russ.)]; Маслянский А.Л., Лапин С.В., Иливанова Е.П., Мазуров В.И., Тотолян А.А. Антикератиновые антитела и антиперинуклеарный фактор являются маркером агрессивного течения ревматоидного артрита // Медицинская иммунология, 2003. Т. 5, № 5-6. С. 599-608. [Maslyansky A.L., Lapin S.V., Ilivanova E.P., Mazurov V.I., Totolian A.A. Antikeratin antibodies and antiperinuclear factor are markers of aggressive rheumatoid arthritis. Meditsinskaya Immunologiya = Medical Immunology (Russia), 2003, Vol. 5, no. 5-6, pp. 599-608. (In Russ.)]; Ajeganova S. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: A 10-year observational cohort study. J. Rheumatol., 2013, Vol. 40, no. 12, pp. 1958-1966.; Bukhari M., Thomson W., Naseem H., Bunn D., Silman A., Symmons D., Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Rheum., 2007, Vol. 56, no. 9, pp. 2929-2935.; Chan S.H., Lin Y.N., Wee G.B., Koh W.H., Boey M.L. HLA class 2 genes in Singaporean Chinese rheumatoid arthritis. Br. J. Rheumatol., 1994, Vol. 33, no. 8, pp. 713-717.; Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. Arthritis Rheum., 1987, Vol. 30, no. 11, pp. 1205-1212.; Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., Schreuder G.M., Wener M., Breedveld F.C., Ahmad N., Lum R.F., de Vries R.R., Gregersen P.K., Toes R.E., Criswell L.A. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum., 2005, Vol. 52, no. 11, pp. 3433-3438.; Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., Rönnelid J., Harris H.E., Ulfgren A.K., Rantapää-Dahlqvist S., Eklund A., Padyukov L., Alfredsson L. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum., 2006, Vol. 54, no. 1, pp. 38-46.; Lee H.S., Lee K.W., Song G.G., Kim H.A., Kim S.Y., Bae S.C. Increased susceptibility to rheumatoid arthritis in koreans heterozygous for HLA-DRB1*0405 and *0901. Arthritis Rheum., 2004, Vol. 50, no. 11, pp. 3468-3475.; Lin L., Chen Y., Xiao Z., Huang S., Yang Z. The association of HLA-DRB1 alleles with rheumatoid arthritis in the Chinese Shantou population: a follow-up study. Biochem. Cell Biol., 2007, Vol. 85, no. 2, pp. 227-238.; Liu S.C., Chang T.Y., Lee Y.J., Chu C.C., Lin M., Chen Z.X., Liu H.F., Dang C.W., Chang S.C., Lee C.S., Chen T.L., Huang C.H. Influence of HLA-DRB1 genes and the shared epitope on genetic susceptibility to rheumatoid arthritis in Taiwanese. J. Rheumatol., 2007, Vol. 34, no. 4, pp. 674-680.; Louzada-Junior P., Freitas M.V.C., Oliveira R.D.R., Deghaide N.H.S., Conde R.A., Bertolo M.B., Donadi E.A. A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrunillated peptide antibodies. Braz. J. Med. Biol. Res., Vol. 41, no. 6, pp. 493-499.; McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med., 2011, Vol. 365, no. 23, pp. 2205-2219.; Okada Y., Kim K., Han B., Pillai N.E., Ong R.T., Saw W.Y., Luo M., Jiang L., Yin J., Bang S.Y., Lee H.S., Brown M.A., Bae S.C., Xu H., Teo Y.Y., de Bakker P.I., Raychaudhuri S. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet., 2014, Vol. 23, no. 25, pp. 6916-6926.; Padyukov L., Suva C., Stolt P., Alfredsson L., Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum., 2004, Vol. 50, no. 10, pp. 3085-3092.; Pursglove M., Murray J., Smyth S. Intermediate Russian: а Grammar and Workbook. Mod. Lang. Rev., 2002, Vol. 97, no. 2, p. 509.; Reviron D., Perdriger A., Toussirot E., Wendling D., Balandraud N., Guis S., Semana G., Tiberghien P., Mercier P., Roudier J. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum., 2001, Vol. 44, no. 3, pp. 535-540.; Scally S.W., Petersen J., Law S.C., Dudek N.L., Nel H.J., Loh K.L., Wijeyewickrema L.C., Eckle S.B., van Heemst J., Pike R.N., McCluskey J., Toes R.E., la Gruta N.L., Purcell A.W., Reid H.H., Thomas R., Rossjohn J. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med., 2013, Vol. 210, no. 12, pp. 2569-2582.; Schellekens G.A., de Jong B.A.W., van den Hoogen F.H.J., van de Putte L.B.A., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest., 1998, Vol. 101, no. 1, pp. 273-281.; Silman A.J., Pearson J.E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res., 2002, Vol. 4, Suppl. 3, pp. S265-S272.; Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med., 1978, Vol. 298, no. 16, pp. 869-871.; Stolt P., Yahya A., Bengtsson C., Källberg H., Rönnelid J., Lundberg I., Klareskog L., Alfredsson L.; EIRA Study Group. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive. Ann. Rheum. Dis., 2010, Vol. 69, no. 6, pp. 1072-1076.; Too C.L., Muhamad N.A., Ilar A., Padyukov L., Alfredsson L., Klareskog L., Murad S., Bengtsson C. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study. Ann. Rheum. Dis., 2015, pp. 1-6.; van der Helm-van Mil A.H.M., Verpoort K.N., Breedveld F.C., Toes R.E.M., Huizinga T.W.J. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res. Ther., 2005, Vol. 7, no. 5, pp. R949-R958.; van der Woude D., Lie B.A., Lundström E., Balsa A., Feitsma A.L., Houwing-Duistermaat J.J., Verduijn W., Nordang G.B., Alfredsson L., Klareskog L., Pascual-Salcedo D., Gonzalez-Gay M.A., Lopez-Nevot M.A., Valero F., Roep B.O., Huizinga T.W., Kvien T.K., Martín J., Padyukov L., de Vries R.R., Toes R.E. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: A meta-analysis of HLA-DRB1 associations with anticitrullinated protein antibody-positive and anti-citrullinated protein. Arthritis Rheum., 2010, Vol. 62, no. 5, pp. 1236-1245.; van Gaalen F.A., van Aken J., Huizinga T.W.J., Schreuder G.M.Th., Breedveld F.C., Zanelli E., van Venrooij W.J., Verweij C.L. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum., 2004, Vol. 50, no. 7, pp. 2113-2121.; Viatte S., Barton A. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease. Eur. Musculoskelet. Rev., 2012, Vol. 7, no. 2, pp. 102-107.; Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol. Microbiol. Scand., 1940, Vol. 17, no. 2, pp. 172-188.; Wakitani S., Imoto K., Murata N., Oonishi H., Ochi T., Yoneda M. An association between the natural course of shoulder joint destruction in rheumatoid arthritis and HLA-DRB1*0405 in Japanese patients. Scand. J. Rheumatol., 1998, Vol. 27, no. 2, pp. 146-148.; Willkens R.F., Nepom G.T., Marks C.R., Nettles J.W., Nepom A.S. Association of HLA-Dw16 with rheumatoid arthritis in Yakima Indians. Further evidence for the “shared epitope” hypothesis. Arthritis Rheum., 1991, Vol. 34, no. 1, pp. 43-47.; Xue Y., Zhang J., Chen Y.M., Guan M., Zheng S.G., Zou H.J. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis. Scand. J. Rheumatol., 2008, Vol. 37, no. 3, pp. 183-187.

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/2019-21-2-15
https://doi.org/10.15789/1563-0625-2019-2-333-340

EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS ; Внесуставные проявления ревматоидного артрита

Συγγραφείς: Yu. V. Muravyev, Ю. В. Муравьев

Πηγή: Rheumatology Science and Practice; Vol 56, No 3 (2018); 356-362 ; Научно-практическая ревматология; Vol 56, No 3 (2018); 356-362 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20183

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, rheumatoid arthritis, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, ревматоидный артрит, ревматоидный фактор

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2572/1719; Тареев ЕМ. К учению о так называемом неспецифическом инфекционном артрите. Советская медицина. 1953;(6):15-21 [Tareev EM. To the doctrine of the so-called nonspecific infectious arthritis. Sovetskaya Meditsina. 1953;(6):15-21 (In Russ.)].; Тареев ЕМ. Висцеральные поражения при системных васкулитах и ревматоидном артрите. Советская медицина. 1956;(5):10-8 [Tareev EM. Visceral lesions in systemic vasculitis and rheumatoid arthritis. Sovetskaya Meditsina. 1956;(5):10-8 (In Russ.)].; Астапенко МГ, Пихлак ЭГ. Болезни суставов. Москва: Медицина; 1966. С. 99-116 [Astapenko MG, Pikhlak EG. Bolezni sustavov [Diseases of the joints]. Moscow: Meditsina; 1966. P. 99-116 (In Russ.)].; Насонов ЕЛ, редактор. Клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2005. 288 с. [Nasonov EL, editor. Klinicheskie rekomendatsii. Revmatologiya [Clinical recommendations. Rheumatology]. Moscow: GEOTARMedia; 2005. 288 p. (In Russ.)].; Каратеев ДЕ, Олюнин ЮА. О классификации ревматоидного артрита. Научно-практическая ревматология. 2008;46(1):5-16 [Karateev DE, Olunin YuA. About classification of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(1):5-16 (In Russ.)]. doi:10.14412/1995-4484-2008-848; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].; Turesson C, O’Fallon WM, Crowson CS, Matteson EL. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29:62-7.; Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford). 1999;38(7):668-74. doi:10.1093/rheumatology/38.7.668; Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother. 2017;8(3):81-6.; Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11(2):123-31. doi:10.1016/j.autrev.2011.09.001; Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis Rheum. 2004;50:3729-31. doi:10.1002/art.20590; Bartels C, Bell C, Rosenthal A, et al. Decline in rheumatoid vasculitis prevalence among US veterans: A retrospective cross-sectional study. Arthritis Rheum. 2009;60:2553-7. doi:10.1002/art.24775; Бестаев ДВ, Каратеев ДЕ, Насонов ЕЛ. Системные проявления ревматоидного артрита. Научно-практическая ревматология. 2013;51(1):76-80 [Bestaev DV, Karateev DE, Nasonov EL. Systemic manifestations of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(1):76-80 (In Russ.)]. doi:10.14412/1995- 4484-2013-1206; Cronstein BN. Interleukin-6 – A key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S11-5.; Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: Results of a case-control study. Ann Rheum Dis. 1996;55:190-2. doi:10.1136/ard.55.3.190; Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int. 1981;1:145-6. doi:10.1007/BF00541260; Turesson C, Jacobsson L, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2006;66:59-64. doi:10.1136/ard.2006.054445; Rojas-Villarraga A, Diaz FJ, Calvo-Paramo E, et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun. 2009;32:64-9. doi:10.1016/j.jaut.2008.11.004; Bergström U, Book C, Lindroth Y, et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol. 1999;28:160-5. doi:10.1080/03009749950154239; Watts RA, Scott DG .Vasculitis and inflammatory arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):916-31. doi:10.1016/j.berh.2016.10.008; Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 2010;5:286-91.; Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752-4. doi:10.1093/rheumatology/35.8.752; Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2010;62:1583-91. doi:10.1002/art.27405; Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11:123-31. doi:10.1016/j.autrev.2011.09.001; Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372-8. doi:10.1164/rccm.201004-0622OC; Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019-27. doi:10.1378/chest.127.6.2019; Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics – A large multicentre UK study. Rheumatology (Oxford). 2014;53:1676-82. doi:10.1093/rheumatology/keu165; Mori S. Management of rheumatoid arthritis patients with interstitial lung disease: Safety of biological antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:41-9. doi:10.4137/CCRPM.S23288; Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814-24. doi:10.1378/chest.12-0741; De Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53- 82. doi:10.1177/1479972310393758; Liote H. Pulmonary manifestation of rheumatoid arthritis. Rev Mal Respir. 2008;25:973-88.; Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-7. doi:10.1161/01.CIR.0000054612.26458.B2; Ortega-Hernandez OD, Pineda-Tamayo R, Pardo AL, et al. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28:767-75. doi:10.1007/s10067-009-1145-8; Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(Suppl 4):iv4-7. doi:10.1093/rheumatology/kel313; Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med (Lond). 2001;1:18-21. doi:10.7861/clinmedicine.1-1-18; Das S, Mohanty M, Padhan P. Outcome of rheumatoid arthritis following adjunct statin therapy. Indian J Pharmacol. 2015;47:605- 9. doi:10.4103/0253-7613.169585; Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: Results from a community based study. Ann Rheum Dis. 2004;63:952-5. doi:10.1136/ard.2003.018101; Agarwal V, Singh R, Wiclaf F, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27:841-4. doi:10.1007/s10067-007- 0804-x; Muramatsu K, Tanaka H, Taguchi T. Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: Diagnosis and options for treatment. Rheumatol Int. 2008;28:951-7. doi:10.1007/s00296-008-0630-8; Ito H, Neo M, Sakamoto T, et al. Subaxial subluxation after atlantoaxial transarticular screw fixation in rheumatoid patients. Eur Spine J. 2009;18:869-76. doi:10.1007/s00586- 009-0945-5; Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1:47-54. doi:10.1038/ncprheum0036; Mielants H, van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27:S56-61.; Korpela M, Mustonen J, Teppo AM, et al. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol. 1997;36:1189-95. doi:10.1093/rheumatology/36.11.1189; Balint GP, Balint PV. Felty’s syndrome. Best Pract Res Clin Rheumatol. 2004;18:631-45. doi:10.1016/j.berh.2004.05.002; Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701. doi:10.1002/art.21675; Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002;31:251-9. doi:10.1080/030097402760375124; Felty AR. Chronic arthritis in the adult associated with splenomegaly and leucopenia. Bull Johns Hopkins Hospital. 1924;35:16-20.; Hanrahan EM, Miller SR. Effect of splenectomy in Felty’s syndrome. JAMA. 1932;99:1247-9. doi:10.1001/jama.1932.02740670035010; Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum. 1980;10:52-65. doi:10.1016/0049-0172(80)90014-1; Barnes CG, Turnbull AL, Vernon-Roberts B. Felty’s syndrome. A clinical and pathological survey of 21 patients and their response to treatment. Ann Rheum Dis. 1971;30:359-74. doi:10.1136/ard.30.4.359; Sienknecht CW, Urowitz MB, Pruzanski W, Stein HB. Felty’s syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis. 1977;36:500-7. doi:10.1136/ard.36.6.500; Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine. 1990;69:69-80. doi:10.1097/00005792-199069020-00001; Denko CW, Zumpft CW. Chronic arthritis with splenomegaly and leukopenia. Arthritis Rheum. 1962;5:478-91. doi:10.1002/art.1780050505; Ruderman M, Miller LM, Pinals RS. Clinical and serological observations on 27 patients with Felty’s syndrome. Arthritis Rheum. 1968;11:377-84. doi:10.1002/art.1780110302; Rosenstein ED, Kramer N. Felty’s and pseudo-Felty’s syndromes. Semin Arthritis Rheum. 1991;21(3):129-42. doi:10.1016/0049- 0172(91)90002-H; Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty’s syndrome. Brit J Rheumatol. 1988;27:191-7. doi:10.1093/rheumatology/27.3.191; Cornwell GG, Zacharski LR. Neutropenia, elevated rheumatoid factor, splenomegaly, and absence of rheumatoid arthritis. Ann Intern Med. 1974;80:555-6. doi:10.7326/0003-4819-80-4-555; Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1:257-9.; Armstrong RD. Fernandes L, Gibson T, et al. Felty’s syndrome presenting without arthritis. Br Med J. 1983;287:1620. doi:10.1136/bmj.287.6405.1620; Moore RA, Brunner CM, Sandusky WR, Leavell BS. Felty's syndrome: long-term follow-up after splenectomy. Ann Intern Med. 1971;75(3):381-5. doi:10.7326/0003-4819-75-3-381; Bucknall RC, Davis P, Bacon PA, Jones JV. Neutropenia in rheumatoid arthritis: studies on possible contributing factors. Ann Rheum Dis. 1982;41:242-7. doi:10.1136/ard.41.3.242; Thorne C, Urowitz MB. Long-term outcome in Felty’s syndrome. Ann Rheum Dis. 1982;41:486-9. doi:10.1136/ard.41.5.486; Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-6. doi:10.1097/BOR.0b013e32835f693f; Watts RA, Ntatsaki E. Refractory rheumatoid vasculitis – a therapeutic dilemma. Oxf Med Case Reports. 2016;2016(11):omw081. doi:10.1093/omcr/omw081; Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 2014;53:145-52. doi:10.1093/rheumatology/ket326; Theander L, Nyhä ll-Wahlin BM, Nilsson JA, et al. Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. J Rheumatol. 2017;44(7):981-7. doi:10.3899/jrheum.161103; Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36:88-98. doi:10.1016/j.semarthrit.2006.04.006; Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol. 2005;32:759-60.; Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should antitumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol. 2006;33:433-4.; Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67:880-4. doi:10.1136/ard.2007.081679; Hellmann M, Jung N, Owczarczyk K, et al. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:929-30. doi:10.1093/rheumatology/ken129; Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Treatment of Raynaud’s phenomenon. Autoimmun Rev. 2008;8:62- 8. doi:10.1016/j.autrev.2008.07.002; Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:206-11. doi:10.1097/00002281-200405000-00007; Turiel M, Sitia S, Atzeni F, et al. The heart in rheumatoid arthritis. Autoimmun Rev. 2010;9:414-8. doi:10.1016/j.autrev.2009.11.002; Mrabet D, Meddeb N, Ajlani H, et al. Cerebral vasculitis in a patient with rheumatoid arthritis. Joint Bone Spine. 2007;74:201-4. doi:10.1016/j.jbspin.2006.08.004; Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12:291-3. doi:10.1097/01.rhu.0000249766.24780.95; Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29:559-61. doi:10.1007/s10067-009-1368-8; Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223-5. doi:10.3109/09273941003739928; Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Br J Rheumatol. 1998;37:908-11. doi:10.1093/rheumatology/37.8.908; Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty's syndrome. Ann Rheum Dis. 2008;67:1352. doi:10.1136/ard.2007.078915; Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009;68:1235-6. doi:10.1136/ard.2008.099267; Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195-7. doi:10.1007/s10067-010-1422-6

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2572
https://doi.org/10.14412/1995-4484-2018-356-362

Особливості клініко-лабораторних показників у хворих на артрит дітей, які мають підвищені титри антитіл до циклічного цитрулінованого пептиду та модифікованого цитрулінованого віментину

Συγγραφείς: Lebets, I.S., Panko, N.O.

Πηγή: Zdorovʹe Rebenka, Vol 8, Iss 2.45, Pp 49-53 (2013)
CHILD`S HEALTH; № 2.45 (2013); 49-53
Здоровье ребенка-Zdorovʹe rebenka; № 2.45 (2013); 49-53
Здоров'я дитини-Zdorovʹe rebenka; № 2.45 (2013); 49-53

Θεματικοί όροι: ювенільний ревматоїдний артрит, антитіла до циклічного цитрулінованого пептиду, антитіла до модифікованого цитрулінованого віментину, діагностика, ювенильный ревматоидный артрит, антитела к циклическому цитруллинированному пептиду, антитела к модифицированному цитруллинированному виментину, диагностика, diagnosis, juvenile rheumatoid arthritis, antibodies to modified citrullinated vimentin, Pediatrics, antibodies to cyclic citrullinated peptide, RJ1-570

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/34eb4ade4dde4f42b43d46c1f7c74f26
http://childshealth.zaslavsky.com.ua/article/download/88227/130949
http://childshealth.zaslavsky.com.ua/article/view/88227
http://childshealth.zaslavsky.com.ua/article/view/88227

SYNOVIAL MEMBRANE CHANGES IN PATIENTS WITH RHEUMATOID ARTHRITIS REVEALED DURING ARTHROSCOPY ; Изменения синовиальной оболочки у больных ревматоидным артритом при артроскопии

Συγγραφείς: E. B. Komarova, Е. Б. Комарова

Πηγή: Rheumatology Science and Practice; Vol 55, No 3 (2017); 241-244 ; Научно-практическая ревматология; Vol 55, No 3 (2017); 241-244 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20173

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, synovial membrane, arthroscopy, disease duration, anti-cyclic citrullinated peptide antibodies, синовиальная оболочка, артроскопия, длительность заболевания

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2375/1575; Dhaouadi T, Sfar I, Abelmoula L, et al. Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review. Tunis Med. 2007;85(12):991-8.; Hitchon CA, El-Gabalawy HS. The synovium in rheumatoid arthritis. Open Rheumatol J. 2011;5:107-14. doi:10.2174/1874312901105010107; Лялина ВВ, Шехтер АБ. Артроскопия и морфология синовитов. Москва: Наука; 2007. 108 с. [Ljalina VV, Shehter AB. Artroskopiya i morfologiya sinovitov [Arthroscopy and morphology of sinovitis]. Moscow: Nauka; 2007. 108 p.].; Klint E, Catrina AI, Matt P, et al. Evaluation of arthroscopy and macroscopic scoring. Arthr Res Ther. 2009;11:R81. doi:10.1186/ar2714; Carl HD, Swoboda B. Effectiveness of arthroscopic synovectomy in rheumatoid arthritis. Rheumatology. 2008;67(6):485-90.; Capitanescu B, Simionescu C, Margaritescu C, et al. Сlinical and morphological aspects of sinovitis in early rheumatoid arthritis. Curr Health Sci J. 2011;37(1):17-20.; Vordenbä umen S, Sewerin P, Lö gters T, et al. Inflammation and vascularisation markers of arthroscopically-guided finger joint synovial biospies reflect global disease activity in rheumatoid arthritis. Clin Exp Rheumatol. 2014 Jan-Feb;32(1):117-20.; Machold KP. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46:342-9. doi:10.1093/rheumatology/kel237; Algergawy SA, Abd El-Sabour M, Osman AS, et al. Early diagnostic and prognostic values of anti-cyclic citrullinated peptide antibody and cartilage oligomeric matrix protein in rheumatoid arthritis. Egypt J Immunol. 2013;20(2):11-20.; Лучихина ЛВ, Каратеев ДЕ. Новые подходы к ранней диагностике артроза и перспективы его патогенетической терапии. Современная ревматология. 2014;8(4):33-8 [Luchikhina LV, Karateev DE. New approaches to early diagnosis of arthrosis and prospects for its pathogenetic therapy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(4):33-8 (In Russ.)]. doi:10.14412/1996-7012-2014-4-33-38; Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol. 2009;90(3):249-61. doi:10.1111/j.1365-2613.2009.00640.x; Marrelli A, Cipriani P, Liakouli V, et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev. 2011;10(10):595-8. doi:10.1016/j.autrev.2011.04.020; Clavel G, Bessis N, Lemeiter D, et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol. 2007;124(2):158-64. doi:10.1016/j.clim.2007.04.014; Раденска-Лоповок СГ. Ревматические заболевания. Морфологическая диагностика: Руководство для врачей. Москва: Практическая медицина; 2014. С. 13 [Radenska-Lopovok SG. Revmaticheskie zabolevaniya. Morfologicheskaya diagnostika: Rukovodstvo dlya vrachey [Rheumatic diseases. Morphological diagnostics: A guide for doctors]. Moscow: Prakticheskaya Meditsina; 2014. Р.13].; Van Oosterhout M, Bajema I, Levarht EW, et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptidepositive rheumatoid arthritis and anti-cyclic citrullinated peptidenegative rheumatoid arthritis. Arthritis Rheum. 2008 Jan;58(1):53- 60. doi:10.1002/art.23148; Boyesen P, Hoff M, Odegard S, et al. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. Arthritis Res Ther. 2009;11(4):R103. doi:10.1186/ar2749; Демидова НВ. Взаимосвязь иммуногенетических и иммунологических маркеров и их влияние на активность заболевания и рентгенологическое прогрессирование у больных ранним ревматоидным артритом. Научно-практическая ревматология. 2009;47(3):12-7 [Demidova NV. Relationship of immunogenetic and immunologic markers and their influence on disease activity and radiological progression in patients with early rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):12-7 (In Russ.)]. doi:10.14412/1995-4484-2009-1307

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2375
https://doi.org/10.14412/1995-4484-2017-241-244

НЕКОТОРЫЕ ОСОБЕННОСТИ ВНЕСУСТАВНЫХ (ЭКСТРААРТИКУЛЯРНЫХ) ПРОЯВЛЕНИЙ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ РЕСПУБЛИКИ СУДАН

Θεματικοί όροι: rheumatoid arthritis, ВНЕСУСТАВНЫЕ ПРОЯВЛЕНИЯ, РЕВМАТОИДНЫЙ АРТРИТ, АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ, RF, extraarticular manifestations, ACPA, РЕВМАТОИДНЫЙ ФАКТОР, 3. Good health

THE ONSET OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS MASKING RHEUMATOID ARTHRITIS ; Дебют АНЦА-ассоциированного системного васкулита под маской ревматоидного артрита

Συγγραφείς: N. F. Frolova, L. V. Korsakova, E. S. Stolyarevich, N. O. Nikonorova, T. V. Beketova, Н. Ф. Фролова, Л. В. Корсакова, Е. С. Столяревич, Н. О. Никонорова, Т. В. Бекетова

Πηγή: Rheumatology Science and Practice; Vol 53, No 6 (2015); 653-656 ; Научно-практическая ревматология; Vol 53, No 6 (2015); 653-656 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20156

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, antineutrophil cytoplasmic antibodies, microscopic polyangiitis, granulomatosis with polyangiitis, rheumatoid arthritis, anticyclic citrullinated peptide antibodies, антинейтрофильные цитоплазматические антитела, микроскопический полиангиит, гранулематоз с полиангиитом, ревматоидный артрит

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2158/1381; Jennette J, Falk R, Bacon P, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65:1–11. doi:10.1002/art.37715; Savage C, Winearls C, Evans D, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985;56:467–83.; Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30. doi:10.1002/1529-0131(199904)42:33.0.CO;2-6; Ahn J, Hwang J, Lee J, et al. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2011;32:2979–86. doi:10.1007/s00296-011-2079-4; Rodgers H, Guthrie J, Brownjohn A, Turney J. Microscopic polyarteritis: clinical features and treatment. Postgrad Med J. 1989;65:515–8. doi:10.1136/pgmj.65.766.515; Pagnoux C, Seror R, Berezne A, et al. Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604–7. doi:10.1016/j.jbspin.2010.02.013; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;(5):33–46 [Beketova TV. Microscopic polyangiitis associated with anti-neutrophil cytoplasmic antibody: clinical features. Terapevticheskii arkhiv. 2015;(5):33–46 (In Russ.)].; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19–28 [Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: clinical features. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2012;50(6):19–28 (In Russ.)].; Noritake D, Weiner S, Bassett L, et al. Rheumatic manifestations of Wegener’s granulomatosis. J Rheumatol. 1987;4(5):949–51.; Tervaert JWC, Damoiseaux J, Boomsma MM, Stegeman CA. Absence of anti-cyclic citrullinated peptide antibodies in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2002;46:849–50. doi:10.1002/art.10087; Elkayam O, Segal R, Lidgi M, et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006;65:1110–2. doi:10.1136/ard.2005.045229; Singh S, Singh U, Kunwar А, Chaurasia N. Anti CCP antibody assay: a diagnostic dilemma in diagnosis of tubercular synovitis. World J Pathol. 2014;3:38–44.; Бадокин ВВ, Трошкина ИА, Александрова ЕН. Ревматоидный фактор и антитела к циклическому цитруллинированному пептиду у больных с псориатическим артритом. Научно-практическая ревматология. 2011;(5):32–7 [Badokin VV, Troshkina IA, Alexandrova EN. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2011;(5):32–7 (In Russ.)].; Vannini A, Cheung K, Fusconi M, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis. 2007;66(4):511–6. doi:10.1136/ard.2006.058933; Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. doi:10.1002/art.27584

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2158
https://doi.org/10.14412/1995-4484-2015-633-656

CHANGES IN THE LEVELS OF ANGIOTENSIN II, ALDOSTERONE, AND FIBROBLAST GROWTH FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN RELATION TO CLINICAL FEATURES ; Изменения уровней ангиотензина ІІ, альдостерона и фактора роста фибробластов у больных ревматоидным артритом в зависимости от клинических особенностей

Συγγραφείς: E. B. Komarova, B. A. Rebrov, Е. Б. Комарова, Б. А. Ребров

Πηγή: Rheumatology Science and Practice; Vol 54, No 2 (2016); 171-174 ; Научно-практическая ревматология; Vol 54, No 2 (2016); 171-174 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20162

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, angiotensin II, aldosterone, fibroblast growth factor, anti-cyclic citrullinated peptide antibodies, ангиотензин II, альдостерон, фактор роста фибробластов

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2212/1428; Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm. 2009;2009:752406. doi:10.1155/2009/752406; Драпкина ОМ. РААС и фиброз. Гепатокардиальные связи. Русcкий медицинский журнал. 2011;19(4):1-6. [Drapkina OM. RAAS and fibrosis. Gepatocardial connection. Rusckiy Meditsinskiy Zhurnal. 2011;19(4):1-6 (In Russ.)].; Biernacka A, Frangogiannis NG. Aging and Cardiac Fibrosis. Aging Dis. 2011 Apr;2(2):158-73.; Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens. 2006 Jun;24(6):983-91. doi:10.1097/01.hjh.0000226182.60321.69; Terada Y, Kuwana H, Kobayashi T, et al. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol. 2008 Feb;19(2):298-309. doi:10.1681/ASN.2007050531; Pattacini L, Casali B, Boiardi L, et al. Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NFkappaB pathway. Rheumatology (Oxford). 2007 Aug;46(8):1252-7. doi:10.1093/rheumatology/kem092; Jacobi J, Maas R, Cordasic N, et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1058-66. doi:10.1152/ajpheart.01103.2007; Соловьев АГ, Резников ЛЛ, Назаров ПГ, Dinarello CA. Провоспалительные цитокининдуцирующие свойства ангиотензина II и механизм антицитокиновых эффектов ингибитора ангиотензинпревращающего фермента каптоприла. Цитокины и воспаление. 2006;5(3):40-5 [Solov’ev AG, Reznikov LL, Nazarov PG, Dinarello CA. Pro-inflammatory properties cytokin-induced angiotensin II and mechanism anticytokine effects of ACE inhibitor captopril. Tsitokiny i Vospalenie. 2006;5(3):40-5 (In Russ.)].; Bunda S, Wang Y, Mitts TF, et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2009 Jun 12;284(24):16633-47. doi:10.1074/jbc.M109.008748; Jeong Y, Chaupin DF, Matsushita K, et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA. 2009 Mar 10;106(10):3782-7. doi:10.1073/pnas.0804037106; Seredyuk V. Role of aldosterone, mitogenic growth factors, apoptosis inducers and pulmonary arterial hypertension in the formation and progression of chronic pulmonary heart disease. Pharm Innovat J. 2013;2(5):36-40.; Fiebeler A, Muller DN, Shagdarsuren E, Luft FC. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens. 2007 Mar;16(2):134-42. doi:10.1097/mnh.0b013e32801245bb; Huang LL, Nikolic-Paterson DJ, Ma FY, Tesch GH. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signaling. Nephron Exp Nephrol. 2012;120(4):e115-22. doi:10.1159/000339500; Sonder SU, Mikkelsen M, Rieneck K, et al. Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br J Pharmacol. 2006 May;148(1):46-53. doi:10.1038/sj.bjp.0706700; Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008 Feb;51(2):432-9. doi:10.1161/HYPERTENSIONAHA.107.103267; Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta. 2007 Jan;375(1-2):10-9. doi:10.1016/j.cca.2006.06.033 17. Aletaha D, Neogi Т, Silman A, et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis Rheum. 2010;62:2569-81. doi:10.1002/art.27584; Tsuneki H, Tokai E, Suzuki T, et al. Protective effects of coenzyme Q10 against angiotensin II-induced oxidative stress in human umbilical vein endothelial cells. Eur J Pharmacol. 2013 Feb 15;701(1-3):218-27. doi:10.1016/j.ejphar.2012.12.027; Яременко ОБ. Клиническая и лабораторная характеристика РА в зависимости от наличия анти-ЦЦП. Украинский ревматологический журнал. 2008;4(34):51-5 [Yaremenko OB. Clinical and laboratory characteristics of RA depending on the availability of anti-CCP. Ukrainskiy Revmatologicheskiy Zhurnal. 2008;4(34):51-5 (In Russ.)].; Algergawy SA, Abd El-Sabour M, Osman AS, et al. Early diagnostic and prognostic values of anti-cyclic citrullinated peptide antibody and cartilage oligomeric matrix protein in rheumatoid arthritis. Egypt J Immunol. 2013;20(2):11-20.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2212
https://doi.org/10.14412/1995-4484-2016-171-174

ИЗМЕНЕНИЯ УРОВНЕЙ АНГИОТЕНЗИНА ІІ, АЛЬДОСТЕРОНА И ФАКТОРА РОСТА ФИБРОБЛАСТОВ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ В ЗАВИСИМОСТИ ОТ КЛИНИЧЕСКИХ ОСОБЕННОСТЕЙ

Συγγραφείς: КОМАРОВА ЕЛЕНА БОРИСОВНА, РЕБРОВ Б.А.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ,АНГИОТЕНЗИН II,АЛЬДОСТЕРОН,ФАКТОР РОСТА ФИБРОБЛАСТОВ,АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/izmeneniya-urovney-angiotenzina-ii-aldosterona-i-faktora-rosta-fibroblastov-u-bolnyh-revmatoidnym-artritom-v-zavisimosti-ot-klinicheskih
http://cyberleninka.ru/article_covers/17022519.png

FEATURES OF ULTRASOUND PARAMETERS AND MARKER OF ANGIOGENESIS IN PATIENTS WITH RHEUMATOID ARTHRITIS DEPENDING OF THE LEVEL ANTI-CCP ; ОСОБЕННОСТИ УЛЬТРАЗВУКОВЫХ ПОКАЗАТЕЛЕЙ И МАРКЕРА АНГИОГЕНЕЗА У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ В ЗАВИСИМОСТИ ОТ УРОВНЯ АНТИТЕЛ К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАНОМУ ПЕПТИДУ

Συγγραφείς: E. B. Komarova, B. A. Rebrov, Е. Б. Комарова, Б. А. Ребров

Πηγή: Medical Herald of the South of Russia; № 4 (2015); 51-55 ; Медицинский вестник Юга России; № 4 (2015); 51-55 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2015-4

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, angiogenesis, vascular endothelial growth, antibodies to cyclic citrullinated peptide, ангиогенез, сосудистый эндотелиальный фактор роста

Περιγραφή αρχείου: application/pdf

Relation: https://www.medicalherald.ru/jour/article/view/261/262; Dhaouadi T., Sfar I., Abelmoula L. et al. Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review // Tunis Med. – 2007.-Vol. 85(12).-P.991-998.; Clavel G. Angiogenesis Markers in Rheumatoid Arthritis / G. Clavel, M. C. Boissier // Future Rheumatol. – 2008. – Vol. 3(2). – P. 153-159.; Марченко Ж. С. Роль сосудистого эндотелиального фактора роста в патогенезе ревматоидного артрита / Ж. С. Марченко, Г. В. Лукина // Научно-практ. ревмат. – 2005. – №1. – С. 57-60.; Taylor P. C. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response; to therapy / P. C. Taylor // Rheumat. – 2005. – Vol. 44(6). – P. 721-728.; Возможности ультразвукового исследования в оценке активности воспалительного процесса и эффективности лечения пациентов с ревматоидным артритом / Г. И. Назаренко, И. Б. Героева, А. Н. Хитрова и др. // Ультразвуковая и функциональная диагностика. – 2007. – № 5. – С. 83-91; Сучасні аспекти імунологічної діагностики раннього ревматоїдного артриту. / О. П. Борткевич, Т. І. Гавриленко, Ю. В. Білявська, Н. О. Рижкова. // Український медичний часопис. – 2009. - № І-ІІ (69). – С. 34-37.; Valesini G. Anticitrullinated protein /peptide antibodies and rheumatoid factors: two distinct autoantibody systems / G. Valesini, C. Alessandri // Arthritis. Res. Ther. – 2009. – Vol. 11. – P. 125.; Яременко О. Б. Клиническая и лабораторная характеристика РА в зависимости от наличия анти ЦЦП / О. Б. Яременко // Украинский ревматологичный журнал. – 2008. - №4(34). - C.51-55.; Kirksey D. Cyclic Citrullinated Peptide Antibody [Электронный ресурс] // Medscape Reference: Aug 2, 2012. URL: emedicine. medscape.com/article/2094136-overview. (дата обращения: 08.12.2014); Ультразвукове дослідження опорно-рухового апарату: Методичні рекомендації / В. М. Коваленко, Н. М. Шуба, О.П. Борткевич та співавт. – Київ, 2008. - 40с.; https://www.medicalherald.ru/jour/article/view/261

Διαθεσιμότητα: https://www.medicalherald.ru/jour/article/view/261
https://doi.org/10.21886/2219-8075-2015-4-51-55

ДЕБЮТ АНЦА-АССОЦИИРОВАННОГО СИСТЕМНОГО ВАСКУЛИТА ПОД МАСКОЙ РЕВМАТОИДНОГО АРТРИТА

Συγγραφείς: ФРОЛОВА Н.Ф., КОРСАКОВА Л.В., СТОЛЯРЕВИЧ Е.С., НИКОНОРОВА Н.О., БЕКЕТОВА ТАТЬЯНА ВАЛЕНТИНОВНА

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА,МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ,ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ,РЕВМАТОИДНЫЙ АРТРИТ,АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ,SYSTEMIC VASCULITIS,ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES,MICROSCOPIC POLYANGIITIS,GRANULOMATOSIS WITH POLYANGIITIS,RHEUMATOID ARTHRITIS,ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/debyut-antsa-assotsiirovannogo-sistemnogo-vaskulita-pod-maskoy-revmatoidnogo-artrita
http://cyberleninka.ru/article_covers/17022678.png

ОСОБЕННОСТИ УЛЬТРАЗВУКОВЫХ ПОКАЗАТЕЛЕЙ И МАРКЕРА АНГИОГЕНЕЗА У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ В ЗАВИСИМОСТИ ОТ УРОВНЯ АНТИТЕЛ К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАНОМУ ПЕПТИДУ

Συγγραφείς: КОМАРОВА Е.Б., РЕБРОВ Б.А.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ,RHEUMATOID ARTHRITIS,АНГИОГЕНЕЗ,ANGIOGENESIS,СОСУДИСТЫЙ ЭНДОТЕЛИАЛЬНЫЙ ФАКТОР РОСТА,VASCULAR ENDOTHELIAL GROWTH,АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ,ANTIBODIES TO CYCLIC CITRULLINATED PEPTIDE

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/osobennosti-ultrazvukovyh-pokazateley-i-markera-angiogeneza-u-bolnyh-revmatoidnym-artritom-v-zavisimosti-ot-urovnya-antitel-k
http://cyberleninka.ru/article_covers/16977214.png

Клиническая информативность определения антител к цитруллинированным белкам при ревматоидном артрите

Συγγραφείς: Черкасова, Мария, Новиков, А., Александрова, Е., Каратеев, Д., Попкова, Т., Лучихина, Е., Авдеева, А., Насонов, Е.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ, РЕВМАТОИДНЫЙ ФАКТОР, АНТИТЕЛА К ЦИТРУЛЛИНИРОВАННЫМ БЕЛКАМ, АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ, АНТИТЕЛА К МОДИФИЦИРОВАННОМУ ЦИТРУЛЛИНИРОВАННОМУ ВИМЕНТИНУ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/klinicheskaya-informativnost-opredeleniya-antitel-k-tsitrullinirovannym-belkam-pri-revmatoidnom-artrite
http://cyberleninka.ru/article_covers/15794706.png

COMPARATIVE CLINICAL, LABORATORY, AND INSTRUMENTAL EVALUATION OF INTERSTITIAL LUNG CHANGES IN RHEUMATOID ARTHRITIS ; Сравнительная клинико-лабораторная и инструментальная характеристика интерстициальных изменений легких при ревматоидном артрите

Συγγραφείς: D. V. Bestaev, L. A. Bozhyeva, N. O. Nikonorova, S. I. Glukhova, D. E. Karateev, E. L. Nasonov, Д. В. Бестаев, Л. А. Божьева, Н. О. Никонорова, С. И. Глухова, Д. Е. Каратеев, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 52, No 3 (2014); 277-282 ; Научно-практическая ревматология; Vol 52, No 3 (2014); 277-282 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20143

Θεματικοί όροι: курение, high-resolution computed tomography, diffusing lung capacity, anti-cyclic citrulli- nated peptide antibodies, rheumatoid factor, C-reactive protein, smoking, компьютерная томография высокого разрешения, диффузионная способность легких, антитела к циклическому цитруллинированному пептиду, ревматоидный фактор, С-ре- активный белок

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1939/1211; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР- Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-Media; 2008. P. 290–331.]; Lee DM,Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11. DOI: http://dx.doi.org/10.1016/S0140- 6736(01)06075-5.; Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 Pt 1):525–35.; Froidevaux-Janin S, Dudler J, Nicod LP, Lazor R. Interstitial lung disease in rheumatoid arthritis. Rev Med Suisse. 2011 Nov 23;7(318):2272–7.; Mayberry JP, Primack SL, Muller NL. Thoracic manifestations of systemic autoimmune diseases: radiographic and high-resolution CT findings. Radiographics. 2000;20(6):1623–35.; Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lungs diseases: CT findings. Radiology. 2004;232(1):81–91. DOI: http://dx.doi.org/10.1148/radiol.2321030174. Epub 2004 May 27.; Webb WR, Muller NL, Naidich DP. High-resolution CT of the lung, 3rd ed. Baltimore: Lippincott, Williams & Wilkins; 2001.; Reynisdottir G, Nyren S, Harju A, et al. Lung changes detected by high resolution tomography are present in ACPA positive RA patients already at disease onset. Am Coll Rheumatol. 2011;63:2176.; Юдин АЛ, Афанасьева НИ, Абович ЮА, Георгиади СГ. Компьютерная томография высокого разрешения; в диагностике интерстициальных пневмоний. Медицинская визуализация. 2002;4:40–8. [Yudin AL, Afanas'eva NI, Abovich YuA, Georgiadi SG. Computer tomography of high resolution in diagnostics the interstitsialnykh of pneumonia. Meditsinskaya vizualizatsiya. 2002;4:40–8. (In Russ.)]; Ascherman DP. Interstitial lung disease in rheumatoid arthritis.Curr Rheumatol Rep. 2010;12(5):363–9. DOI:10.1007/s11926-; 0116-z.; Cervantes-Peres P, Toro-Perez AH, Rodriguez-Jurado P. Pulmonary inwolvement in rheumatoid arthritis. JAMA. 1980;243(17):1715–59. DOI: http://dx.doi.org/10.1001/jama.1980.03300430017014.; Liu G, Friggeri A, Yang Y, Milosevic J, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207(8):1589–97. DOI:10.1084/jem.20100035. Epub 2010 Jul 19.; Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associ- ated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22 Spec No:S151–65. DOI: http://dx.doi.org/10.1148/radiographics.22.suppl_1.g02oc04s151.; Демина AB, Раденска-Лоповок СГ, Фоломеева ОM, Эрдес Ш. Причины смерти у больных с ревматическими заболеваниями в Москве. Терапевтический архив. 2005;77(4):77–82. [Demina АВ, Radaneska-Lopovok SG, Folomeeva OM, Erdes Sh. Causes of death in patients with rheu- matic diseases in Moscow. Terapevticheskii arkhiv. 2005;77(4):77–82. (In Russ.)]; Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91. DOI: http://dx.doi.org/10.1002/art.27405.; Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung diseases. The relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397–405. DOI:10.1378/chest.09-0444.; Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis. 2006 Mar;65(3):366–71. DOI: http://dx.doi.org/10.1136/ard.2005.041079. Epub 2005 Jul 13.; Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41(5):817–22. DOI: http://dx.doi.org/10.1002/1529- 0131(199805)41:5%3C817::AID-ART7%3E3.0.CO;2-S.; Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–66. DOI:10.1001/archinternmed.2007.59.; Rajasekaran AB, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis; a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford). 2001;40(9):1022–5. DOI: http://dx.doi.org/10.1093/rheumatol- ogy/40.9.1022.; Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS task force. Standardization of spirometry. Eur Resp J. 2005;26(2):319–38. DOI: http://dx.doi.org/10.1183/09031936.05.00034805.; Черняк АВ, Неклюдова ГВ. Диффузионная способность легких. В кн.: Функциональная диагностика; в пульмонологии. Практическое руководство. Под ред.; А.Г. Чучалина. Москва: Атмосфера; 2009. С. 94. [Chernyak AV, Neklyudova GV. Diffusive ability of lungs. In: Funktsional'naya diagnostika v pul'monologii. Prakticheskoe rukovodstvo [Functional diagnostics in pulmonology. Practical Guide]. Chuchalin AG, edi- tor. Moscow: Atmosfera; 2009. P. 94.]; Wedzicha JA, Bestall JC, Garrod R, et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pul- monary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1999;12(2):363–9. DOI: http://dx.doi.org/10.1183/09031936.98.12020363.; Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429–35. DOI: http://dx.doi.org/10.1007/s00296-004-0472-y.; Giles JT, Danoff SK, Sokolove J, et al. Association of fine speci- ficity and repertoire expansion of anticitrullinated peptide anti- bodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2013 May 28. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-203160.; Inui N, Enomoto N, Suda T, et al. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthri- tis. Clin Biochem. 2008 Sep;41(13):1074–7. DOI:10.1016/j.clin- biochem.2008.06.014. Epub 2008 Jul 3.; Mohd Noor N, Mohd Shahrir MS, Shahid MS, et al. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis. 2009 Jul;12(2):136–44. DOI:10.1111/j.1756-185X.2009.01376.x.; Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung dis- ease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28(5):611–3. DOI:10.1007/s10067-009-1128-9. Epub 2009 Feb 28.; Klareskog L, Stolt P, Lundberg K, et al. Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA- DR (shared epitope) – restricted immune reactions to autoanti- gens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. DOI: http://dx.doi.org/10.1002/art.21575.; Baka Z, Edit Buzas E, Nagy G. Rheumatoid arthritis and smok- ing: putting the pieces together. Arthritis Res Ther. 2009;11(4):238–41. DOI: http://dx.doi.org/10.1186/ar2751.; Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, et al. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA- DRB1 shared epitope alleles. Arthritis Rheum. 2007;56(9):2913–8. DOI: http://dx.doi.org/10.1002/art.22845.; Demoruelle M, Weisman M, Derber L, et al. Lung abnormalities in subjects with elevations of rheumatoid arthritis-related autoanti- bodies without arthritis by examination and imaging suggest the lung is an early and perhaps initiating site of inflammation in rheumatoid arthritis. Ann Rheum Dis. 2012;71:A25 DOI:10.1136/annrheumdis-2011-201231.16.; Padyukov L, Silva C, Stolt P, et al. A gene environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50(10):3085–92. DOI: http://dx.doi.org/10.1002/art.20553.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/1939
https://doi.org/10.14412/1995-4484-2014-277-282